Advertisements
Feeds:
Posts
Comments

Posts Tagged ‘Scientific method’


The Arrigo Recordati International Prize for Scientific Research

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 7/16/2018

2015 ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN JOSEPH VALENTINE MCMURRAY AND SALIM YUSUF

The Prize was awarded to the two scientists for their contribution in researching secondary prevention and risk reduction strategies for patients with cardiovascular diseases.

Milan, June 13, 2015

Today the Eighth Edition of the Arrigo Recordati International Prize for Scientific Research came to its conclusion with 100,000 Euros being awarded to Professor John Joseph Valentine McMurray, Professor of Medical Cardiology and convener for clinical research in the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, Scotland, UK and Professor Salim Yusuf, Professor of Medicine, Executive Director of the Population Health Research Institute (PHRI), McMaster University, Hamilton, Canada.

The ceremony took place during the 25th European Society of Hypertension (ESH) Annual Meeting in Milan.

The Arrigo Recordati International Prize for Scientific Research was established in 2000, in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati, who led the homonymous company through a period of intense growth and development for 48 years until his premature death in February 1999. The Prize recognizes the seminal work of an individual who has demonstrated, through dedication to research, the values recognized by Arrigo Recordati, by granting every two years a prize of 100,000 Euros to a distinguished scientist, of any nationality, working in an institutional setting and not affiliated with pharmaceutical or medical device companies, for his/her commitment and accomplishments in the field of cardiovascular disease. Each edition of the Prize is devoted to a specific theme in this field.

For the 2015 Edition of the Prize, relevant International Societies and organizations specializing in the areas of Cardiology and Internal Medicine were invited to nominate candidates that they felt merited the Award for lifetime ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN JOSEPH VALENTINE MCMURRAY AND SALIM YUSUF achievement in researching secondary prevention and risk reduction strategies for patients with cardiovascular diseases.Self-nominations were not considered. The Jury panel of the 2015 Edition of the Prize, who announced the final decision, is composed of experts who have provided leadership throughout their long careers in the field of cardiology and secondary prevention and risk reduction strategies for patients with cardiovascular diseases.

The Jury is chaired by M. John Chapman B.Sc. (Hons), Ph.D., D.Sc., FESC, Research Professor, Medical Faculty of the Pierre and Marie Curie University (UPMC), Paris, Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit, (INSERM), Pitié-Salpêtrière University Hospital, Paris, France, Past-President of the European Atherosclerosis Society (EAS). Members of the Jury are Thomas F. Lüscher MD, FRCP, Professor and Chairman of Cardiology, University Heart Center, Zurich, Director of Center for Molecular Cardiology, University of Zurich, Switzerland and Chris J. Packard CBE, Ph.D., FRCPath, D.Sc. FRCP(Gla), FRSE, Director of Research and Development, NHS Greater Glasgow & Clyde, Honorary Professor of Vascular Biochemistry at the University of Glasgow, Consultant Clinical Scientist, Department of Biochemistry, NHS Greater Glasgow & Clyde, Scotland, UK. Professor Chapman, on behalf of the Jury, officially awarded the winners with the following motivation:

“Unique and exceptional contributions of each candidate to studies and clinical trials in secondary prevention, to the impact of their works on development of new strategies for risk reduction in subjects with CVD”. The winners of the Arrigo Recordati Prize, after expressing their satisfaction for the important Award, gave a brief lecture summarizing their research efforts and results in the study of the secondary prevention and risk reduction strategies for patients with cardiovascular diseases.

Over the last 3 decades, Professor Salim Yusuf has built capacity for clinical and population research across the world by establishing networks at over 1500 sites in 85 countries, spanning all inhabited continents of the world. He has trained over 100 researchers, many of whom are internationally renowned leaders in medical research. He has helped develop major research institutes or programs in Canada, India, Argentina, Brazil, South Africa, Saudi Arabia, Malaysia, and China. Throughout his professional career, Professor John Joseph Valentine McMurray has published approximately 700 original papers, reviews, and book chapters, including several in leading medical (e.g. Goldman Cecil’s) and cardiology textbooks (e.g. The ESC Textbook on Cardiovascular Medicine). He is the primary author or editor of thirteen books.

Professor McMurray was recently identified as one of the 400 most influential biomedical researchers in the world and the only cardiovascular researcher on this list from the UK (Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers,1996-2011. Eur J Clin Invest. 2013;43:1339-65). He was also included in the new 2014 Highly Cited Researchers listing and one of The World’s Most Influential Scientific Minds.

The theme of the 2017 Edition of the Arrigo Recordati Prize will be: “Biological therapies for the treatment of diseases and conditions with high cardiovascular risk”.

Finally, Giovanni Recordati, Arrigo Recordati’s son and current Chairman and CEO of the Recordati pharmaceutical company, renewed the Company‘s strong commitment to research and officially announced that the theme chosen for the Nineth Edition of the Arrigo Recordati Prize is: “Biological therapies for the treatment of diseases and conditions with high cardiovascular risk”. A large body of evidence now indicates that several chronic diseases and conditions are associated with a high cardiovascular (CV) risk. This is largely documented also for autoimmune diseases such as rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus. Indeed, it is now well established that in rheumatoid arthritis (RA) the risk of CV morbidity and mortality is increased by almost 50%, as compared with the general population, and that CV disease is the leading cause of death in these patients. Large studies in RA patients have shown an almost 2-fold increase in their risk for myocardial infarction, to a level comparable to that observed in patients with type-2 diabetes. Recognized CV risk factors (such as hypertension, smoking and type-2 diabetes) certainly contribute to the increased CV risk level in RA patients, but do not fully explain it. Rather, growing evidence suggests that the chronic systemic inflammatory burden associated with RA is a key element of the increased CV risk. In the past decade, important new findings have emerged linking also psoriasis with chronic systemic inflammation and a subsequent increase in CV risk. High-need psoriatic patients show a high prevalence of CV risk factors, and may consequently be predisposed to CV diseases. A significantly higher prevalence of obesity, smoking, and hypertension was found for high-need psoriatic patients compared with controls. Striking differences were found with respect to body mass index and obesity (more than 35% of all high-need psoriatic patients were found to be obese). Furthermore, the associations between psoriasis and CV risk factors are reported to be stronger as psoriasis severity increases. As this is relevant for therapy management in everyday clinical practice, CV risk should be evaluated for each high-need psoriasis patient, before and during systemic treatment. All the above evidence indicates that the study and survey of the prevalence of CV risk factors in patients with chronic diseases and conditions, and in particular with autoimmune diseases, is highly relevant. It has been proposed that an effective control of inflammation could help reduce CV risk and illness in patients with autoimmune diseases. Growing clinical evidence has shown the increasing efficacy of therapies and therapeutic strategies, largely based on the use of biological products, in significantly reducing disease activity and the CV risk level in autoimmune diseases. On the other hand, it also has to be carefully assessed whether these biological therapies are safe for the treatment of diseases and conditions with high CV risk. At this point, it is encouraging that a recent meta-analysis evaluating a possible association between biological therapies for psoriasis and major adverse cardiovascular events (MACEs) did not show a significant increase in risk associated with the use of biological therapies.

SOURCE

http://www.recordati.com/resources/Pubblicazione/___f62376e579e74cea87b51c3f84292263_/2015-arrigo-recordati-prize.pdf

THE PIVOTAL ROLE OF MICROCIRCULATION IN SYSTEMIC AND ORGAN DISEASES

The term “microcirculation” describes the network of small vessels embedded within the organs that are responsible for the distribution of blood and the fluid exchanges within the tissues. Thus, microcirculation differs from macrocirculation, which is formed by larger vessels that transport blood to and from the organs.

The vessels on the arterial side of the microcirculation, the arterioles (10-100 µm in diameter) are well innervated and surrounded by smooth muscle cells. Arterioles carry the blood to the capillaries (about 5-8 µm in diameter) which are not innervated and have no smooth muscle cells. Fluid exchange between the capillaries and the tissues takes place at the capillary bed. Blood then flows out of the capillaries into the venules (10-200 µm in diameter) which have little smooth muscle, and finally blood flows from the venules into the veins. In addition to these blood vessels, the microcirculation also includes lymphatic capillaries and collecting ducts. It is important to note that blood is supplied to all parts of the body at all times, but all capillary beds do not contain blood at all times. Blood is diverted to the parts of the body that need it most at a particular time.

The main functions of the microcirculation include the regulation of:
1. blood flow and tissue perfusion
2. blood pressure,
3. tissue fluid (swelling or edema),
4. delivery of oxygen and other nutrients and removal of CO2 and other metabolic waste products, and
5. body temperature.

Therefore, microcirculation is a complex system that plays an important role in the hemodynamics of the body, by regulating blood pressure and venous return to the heart. It regulates the balance between oxygen demand and supply of parenchymal cells. In addition, microcirculation interacts extensively with the immune system and the body’s defense mechanisms.

The pivotal role of microcirculation in many disease conditions is well established. Indeed, microcirculation abnormalities often occur in subjects with high blood pressure. Also, metabolic diseases such as dislipidemia and type-2 diabetes induce destructive changes in the microvascular system that feeds the heart, the retina and the kidneys. As a consequence, early symptoms affecting patients, often the first signs of an underlying and more serious disease, can be due to a disturbance of microcirculation. Thus, microcirculation is an essential factor, albeit often poorly recognized, in the pathogenesis of many disease conditions.

With the constant improvement of diagnostic tools, scientists and physicians have realized that many problems affecting patients may occur in the microcirculatory system. Novel techniques have made it possible for the microcirculation to be observed directly at the patient’s bedside. Currently, research using these new techniques is focusing at the central role of the microcirculation in critical diseases. Experimental studies have demonstrated differences in microvascular alterations between models of septic and hypovolemic shock. In human studies, the microcirculation has most extensively been investigated in septic syndromes and has revealed highly heterogeneous alterations with clear evidence of arteriolar-venular shunting. Until now, the microcirculation in acute heart failure syndromes such as cardiogenic shock has scarcely been investigated.

Recordati at a Glance

Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals for primary care as well as orphan drugs for the treatment of rare diseases. Headquartered in Milan, it has operations in the main European countries, in Russia and other Central and Eastern European countries, in Turkey and in the United States of America. Recordati has been listed on the Italian Stock Exchange since 1984.

Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases. A field force of more than 1700 medical representatives promotes these products in all countries where subsidiaries have been established. The company’s leading products are drugs for the treatment of hypertension and other cardiovascular disorders as well as treatments for disorders of the lower urinary tract such as benign prostatic hyperplasia. Drugs for rare diseases are mainly treatments for metabolic deficiencies of a genetic nature. Recordati sells its proprietary pharmaceuticals directly to the market in the countries where it is present and through licensees elsewhere. Pharmaceutical production is based mainly in Italy (Milan), France (Montluçon) and Turkey (Esenyurt). Plants for the production of proprietary active ingredients are situated in Italy (Campoverde, Latina) and in Cork (Ireland).

Pharmaceutical research is focused on the discovery of new chemical entities for the treatment of urogenital conditions while development activities are concentrated on urology, on the area of rare diseases and on the cardiovascular therapeutic area.

Recordati also has a minor pharmaceutical chemicals business. Recordati produces active ingredients for both its own proprietary pharmaceuticals and for the generic drugs industry. Over 90% of third party production is for the export markets.

Key consolidated data

  • Consolidated revenue for 2012 is € 828.3 million.
  • Operating income for 2012 is € 167.0 million.
  • Net income for 2012 is € 118.5 million.

Strategy

  • Continue its commitment to research and development mainly in the urological and cardiovascular areas and in treatments for rare diseases. Special care is a priority in the product development pipeline.
  • Expand through organic development and through acquisitions.
  • Pursue geographical expansion by entering new markets characterized by high growth potential.
  • Develop sales of orphan drugs globally.

HISTORY OF THE AWARD

Arrigo Recordati Profile

“Research is the only true engine of growth for the pharmaceutical industry”
Arrigo Recordati

Arrigo Recordati believed research was the most powerful asset for the pharmaceutical industry. He became head of the family business in 1951, at the age of 23, and transformed the family pharmaceutical laboratory employing 325 people into an international company listed on the Italian Stock Exchange. Arrigo Recordati’s remarkable life came to a premature end at the age of 71, in 1999.

Under his direction, in 1953 the company’s headquarters and pharmaceutical plant moved from Correggio, a small town in the Emilia region of Italy, to Milan, the capital of Italian business. During this time Arrigo Recordati provided the company with a stronger competitive advantage by updating its research facilities with advanced pharmacological laboratories.

In the 1950s and 60s, Arrigo Recordati relied on two strong beliefs: scientific research and internationalization. To maximize the results of Recordati research, he established subsidiaries in Brazil and Mexico. Arrigo Recordati also fostered a close relationship with the United States, signing among other things a strategic partnership agreement with Syntex Corporation (acquired by Roche Corporation in 1990) – at that time a company involved in cutting-edge research on the synthesis of steroid hormones.

Arrigo Recordati strongly believed in the power of scientific research to drive the growth of the pharmaceutical industry and provide products beneficial to public health and individual well being. Efloxate (1955), a coronary vasodilator for the treatment of cardiovascular disease, was the first compound to originate from Recordati’s research laboratories during Arrigo Recordati’s leadership. Other original molecules developed and marketed during his leadership include: dimefline (1958), a respiratory analeptic, flavoxate (1957), a urinary anti-spasmodic, tibezonium iodide (1971), an oral antiseptic, fenticonazole (1978), an antimycotic and lercanidipine (1984), a calcium channel blocker for the treatment of hypertension. In particular, flavoxate was the first original New Chemical Entity developed by an Italian company to be approved by FDA.

Arrigo Recordati also believed that even small companies – if managed with vigor and imagination – can compete effectively in the pharmaceutical arena. In 1984 Recordati was listed on the Italian Stock Exchange, completing its transformation from a small, family-run operation to a modern, professional, publicly listed company.

Recordati continues to dedicate a substantial amount of its resources to research and development, specializing in urological and cardiovascular therapies as well as treatments for rare diseases.

After 48 years of intense and challenging leadership, Arrigo Recordati passed away, leaving a solid, international business projected into the future.

INFORMATION ON THE AWARD

Mission

The Arrigo Recordati International Prize for Scientific Research was established in the year 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati and aims to promote scientific research in the field of cardiovascular disease.

The award is presented every two years to a scientist who has demonstrated dedication to the advancement of scientific knowledge in cardiology.

The Prize 2013

The seventh edition of the International Prize in 2013 was awarded to a clinical or basic science investigator who, through his work, has achieved distinction in the study of the pivotal role of microcirculation in systemic and organ diseases.

The Prize awarded 100,000 Euros to the winner.

Scientists of all nationalities who work in an institutional setting and are not affiliated with a pharmaceutical company or medical device company are eligible.

The winner of the Prize was announced during an awards ceremony on the 15th of June 2013 in Milan, Italy, during the 23rdESH (European Society of Hypertension) Annual Meeting.

Latest Press Release

2013 Arrigo Recordati International Prize for Scientific Research.
The pivotal role of microcirculation in systemic and organ diseases

Award Regulations

The Prize

The Arrigo Recordati International Prize for Scientific Research is awarded every two years to a scientist who has shown special distinction in the area of cardiovascular disease or the study of biochemical mechanisms of particular importance in the same therapeutic field.

Each edition is devoted to a specific theme in the cardiovascular therapeutic field. The Prize is open to researchers of all nationalities who are not in any case directly affiliated with a pharmaceutical company or medical device company.

The Prize winner receives a sum of 100,000 Euros.

The Theme

The seventh edition of the Prize in 2013 recognized a clinical or basic science investigator who has achieved distinction in the study of the pivotal role of microcirculation in systemic and organ diseases.

Selection Procedures

The candidates were selected on the basis of nominations from scientific societies around the world.

The nominees were evaluated and a winner selected by a Judging Panel of three world-renowned cardiologists.

Jury

Members of the Jury of the 2013 edition:

Mara Lorenzi, MD (Panel Chairman), Professor of Ophthalmology, Harvard Medical School, Senior Scientist and George and Frances Levin Scholar in Diabetic Retinopathy, Schepens Eye Research Institute Massachusetts Eye and Ear, Boston, MA, USA.

Dr Ignatios Ikonomidis, MD, Ph.D., FESC, Assistant Professor in Cardiology, Director of the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens Attikon University Hospital, Athens, Greece.

Can IncePh.D., Professor in Clinical Physiology, Dept. of Translational Physiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, Dept. of Intensive Care Adults, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Nomination Procedures
Nominations have to be decided and proposed by scientific societies and organizations invited to submit their candidates.

Each nominator is allowed to submit more than one nominee for the Award.

Self nominations will not be considered.

Nominations will be sent in electronic format, through the dedicated website www.recordati.com/prizewith the use of a password assigned to scientific societies invited to nominate.

The deadline for nominations for the 2013 award was February 28, 2013.

The information received is held strictly confidential. Only those involved in the Prize selection procedure have access to the material submitted. The Judging Panel requires the same discretion by those making nominations.

Announcement of the Winner

The winner was notified with an official letter following the Judging Panel decision and was invited to give a lecture during the awards Ceremony.

Award Ceremony

The winner of the Prize was announced during an awards ceremony on the 15th of June 2013 in Milan, Italy, during the 23rd ESH (European Society of Hypertension) Annual Meeting.

Prize Winners: 2001 – 2013

Filippo Crea, MD
2013 Prize Winner

The Prize was awarded to the scientist for his contribution in researching the pivotal role of microcirculation in systemic and organ diseases.

The theme of the 2015 Edition of the Arrigo Recordati Prize will be: “Secondary prevention and risk reduction strategies for patients with cardiovascular diseases”.

Milan, June 15, 2013

Today the seventh edition of the Arrigo Recordati International Prize for Scientific Research came to its conclusion with 100,000 Euros being awarded to Prof. Filippo Crea, Full Professor in Cardiology at Policlinico “Agostino Gemelli”, Rome, Italy. The ceremony took place during the 23rd ESH (European Society of Hypertension) Annual Meeting in Milan.

The Arrigo Recordati International Prize for Scientific Research was established in 2000, in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati, who led the homonymous company through a period of intense growth and development for 48 years until his premature death in February 1999. The Prize recognizes the seminal work of an individual who has demonstrated, through dedication to research, the values recognized by Arrigo Recordati, by granting every two years a prize of 100,000 Euros to a distinguished scientist, of any nationality, working in an institutional setting and not affiliated with pharmaceutical or medical device companies, for his/her commitment and accomplishments in the field of cardiovascular disease. Each edition of the Prize is devoted to a specific theme in this field.

For the 2013 edition of the Prize, relevant international societies and organizations were invited to nominate candidates that they felt merited the award for lifetime achievement in researching the pivotal role of microcirculation in systemic and organ diseases. Self-nominations were not considered.

The Jury panel of the 2013 edition of the Prize, who announced the final decision, is composed of experts who have provided leadership throughout their long careers in the field of cardiology and microcirculation. The jury is chaired by Mara Lorenzi, MD, Professor of Ophthalmology, Harvard Medical School, Senior Scientist and George and Frances Levin Scholar in Diabetic Retinopathy, Schepens Eye Research Institute Massachusetts Eye and Ear, Boston, MA, USA. Members of the Jury are Ignatios Ikonomidis, MD, Ph.D., FESC, Assistant Professor in Cardiology, Director of the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens Attikon University Hospital, Athens, Greece and Can Ince, Ph.D., Professor of Clinical Physiology, Dept. of Translational Physiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, Dept. of Intensive Care Adults, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Professor Lorenzi, on behalf of the Jury, officially awarded the winner with the following motivation: “The Recordati Prize recognizes Professor Filippo Crea for his outstanding contributions in researching the pivotal role of microcirculation in systemic and organ diseases”.

The winner of the Arrigo Recordati Prize, after expressing his satisfaction for the important award, gave a brief lecture summarizing his research efforts and results in the study of the pivotal role of microcirculation in systemic and organ diseases.

Throughout his professional career, Professor Filippo Crea has kept a consistent focus on clinical conditions related to dysfunction of the coronary microcirculation, identifying the clinical impact of events occurring in the coronary microcirculation, uncovering mechanisms, and pioneering therapeutic approaches.

Finally, Giovanni Recordati, Arrigo Recordati’s son and current Chairman and CEO of the Recordati pharmaceutical company, renewed the Company‘s strong commitment to research and officially announced that the theme chosen for the eighth edition of the Arrigo Recordati Prize is: “Secondary prevention and risk reduction strategies for patients with cardiovascular diseases”.

Every year, millions of people are admitted to hospitals and intensive care units following acute cardiovascular events. Most of these patients receive “state of the art” medical and interventional care during their hospitalization.

However, observational data suggest that, after discharge from the hospital, patients are neither properly followed nor receive appropriate evidence-based treatments, even though a large body of evidence supporting the value and effectiveness of secondary prevention of acute cardiovascular events is currently available.

Thus, it seems clear that secondary prevention is not fully implemented in many cases of acute cardiovascular events. Secondary prevention should aim to reduce the risk of these events, thus reducing the need for interventional procedures, improving quality of life and in the end, extend survival of the affected patients.

Important new evidence has emerged that further supports and broadens the merits of intensive and comprehensive risk-reduction therapies for patients with cardiovascular diseases, including atherosclerotic vascular disease and peripheral artery diseases. Evidence-based recommendations and guidelines for secondary cardiovascular prevention are available, and are the key reference for clinical intervention. Therapeutic lifestyle changes including identification and treatment of established risk factors (especially hypertension, smoking, dyslipidemia, diabetes, obesity or poor diet, and physical inactivity) are of proven benefit and are regarded as major strategies to improve outcomes and diminish premature morbidity and mortality from cardiovascular diseases (CVD). Adjunctive drug therapies (such as aspirin, statins, anti-hypertensive drugs) have proven benefits.

The great impact of innovative scientific and clinical research accomplished in the field of secondary prevention and risk reduction strategies for patients with cardiovascular diseases must be recognized and acknowledged.

The Arrigo Recordati Prize in its next edition of 2015 will seek to identify a leading contributor in this highly relevant area of medical research.

Filippo Crea was born in Cosenza, Italy on 19 September 1953. He graduated from Pisa Medical School with full honours in 1977 and passed the Postgraduate Boards in both Pulmonary and Cardiovascular Diseases, again with full honours, at Pisa Medical School in 1980 and 1983 respectively. During the whole of 1984 he was Research Fellow at the Division of Cardiology of the University of Florida, directed by Professor Richard C. Conti. From 1985 to 1991 he was Honorary Clinical Assistant and then Senior Lecturer and Honorary Consultant at the Cardiovascular Research Unit of the Hammersmith Hospital in London, directed by Professor Attilio Maseri. He returned to Italy upon his appointment as Chief of the Catheterization Laboratory at the Institute of Cardiology of the Catholic University in Rome. In 2000 he became Associate Professor of Cardiology and Chief of the Intensive and Sub-Intensive Care Units. In 2001 he became Professor of Cardiology, Director of the Institute of Cardiology and Director of the Postgraduate School in Cardiology at the Catholic University in Rome. Since October 2008 he has been Director of the Department of Cardiovascular Sciences.

He is a Fellow of the American College of Cardiology and of the European Society of Cardiology, Past Chairman of the Working Group on “Coronary Pathophysiology and Microcirculation” and Past Member of the Congress Programme Committee of the European Society of Cardiology.

He is Associate Editor of the “European Heart Journal”, member of the Editorial Board of “Circulation”, “Clinical Cardiology” and “Revista Espagñola de Cardiologia”, past Associate Editor of “Heart” and past Deputy Editor of the “Italian Heart Journal”.

In 1992 he received the Newburg Prize for his scientific contribution to cardiovascular research from Professor Rita Levi Montalcini.

His main fields of interest are coronary microvascular dysfunction, mechanisms of acute coronary syndromes and pathophysiology of stem cells in coronary artery disease.

He is the author of more than 650 publications in peer-reviewed journals with an impact factor of more than 3900 and H-Index of 60. He has contributed to several multi-author textbooks. In particular, he is the author of the Chapter on Chronic Ischaemic Heart Disease of the ESC Textbook of Cardiovascular Medicine published in 2009 and author of a book entitled Coronary Microvascular Dysfunction (in press).

2011 Prize Winner

Lindsey D. Allan

Lindsey Allan is currently Professor of Fetal Cardiology at King’s College, London. She started her research in fetal cardiology in 1980 with a grant from the British Heart Foundation. Subsequent grant requests were also successful and led to the establishment of a BHF group under her direction, which continued until 1993. In 1992, she was awarded a personal chair by the Foundation. She then held an appointment as Professor of Pediatrics at Columbia University of New York between 1993 and 2000. She returned to London to her current post at King’s College Hospital, London in 2001.

She has published almost 200 peer-reviewed original articles on the subject of fetal cardiology, as well as many review articles. She is on the Editorial Board of several journals, including Ultrasound in Obstetrics and Gynecology, Prenatal Diagnosis and Cardiology in the Young. She has published 4 textbooks, “Manual of Fetal Echocardiography” in 1986, “Atlas of Fetal Cardiology” in 1992, “Fetal Cardiology” in 2000 and “A Practical guide to Fetal Echocardiography” in 2008, as well as contributing to several multi-author textbooks. She was awarded the Ian Donald Gold Medal for ultrasound in 1998 and is an honorary member of the American Society of Maternal-Fetal Medicine.

After receiving her medical degree from Glasgow University in 1969, she became a member of the Royal College of Physicians and Surgeons of Glasgow in 1972. A research year in Genetics in 1973 stimulated her interest in prenatal diagnosis, which later became focused on the heart when ultrasound technology advanced to a stage where real-time imaging of the heart became possible in 1980. She was a fellow in paediatric cardiology between 1980-82 at Guy’s Hospital in London, where she continued her research until 1993. She completed her MD thesis in 1983. She became a Fellow of the Royal College in 1986. She was an attending physician at Babies Hospital, Columbia Presbyterian Medical Center between 1993 and 2000 and has been a consultant at King’s College, London since 2001.

2009 Prize Winner

Valentin Fuster

Dr. Fuster serves The Mount Sinai Medical Center as Director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health. He is the Richard Gorlin, MD/Heart Research Foundation Professor, Mount Sinai School of Medicine. Dr. Fuster is also the President of Science of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain.

Among the seemingly countless positions of distinction that he holds are Past President of the American Heart Association, Immediate Past President of the World Heart Federation, a member of the Institute of Medicine of the National Academy of Sciences where he serves as Chair of the committee on Preventing the Global Epidemic of Cardiovascular Disease, a former member of the National Heart, Lung and Blood Institute Advisory Council, and former Chairman of the Fellowship Training Directors Program of the American College of Cardiology. Twenty-six distinguished universities throughout the world have granted him Doctor Honoris Causa.

Dr. Fuster is the recipient of one major ongoing NIH grant. He has published more than 750 articles on the subjects of coronary artery disease, atherosclerosis and thrombosis, and he has become the lead Editor of two major textbooks on cardiology, ‘The Heart’ (previously edited by Dr. J. Willis Hurst) and “Atherothrombosis and Coronary Artery Disease” (with Dr. Eric Topol and Dr. Elizabeth Nabel). Dr. Fuster has been appointed Editor-in-Chief of the Nature journal that focuses on cardiovascular medicine (Nature Reviews, Cardiology, April 2009) and he is the Editor of the new “AHA Guidelines and Scientific Statements Handbook”, which compiles all the latest information.

Dr. Fuster is the only cardiologist to receive the two highest gold medal awards and all four major research awards from the four major cardiovascular organizations: The Distinguished Researcher Award (Interamerican Society of Cardiology, 2005 and 2009), Andreas Gruntzig Scientific Award and Gold Medal Award (European Society of Cardiology, 1992 and 2007 respectively), Gold Medal Award and Distinguished Scientist (American Heart Association, 2001 and 2003 respectively), and the Distinguished Scientist Award (American College of Cardiology, 1993).

In addition, he has received the Lewis A. Conner Memorial Award by the American Heart Association, the James B. Herrick Achievement Award from the Council of Clinical Cardiology of the American Heart Association, and the 1996 Principe de Asturias Award of Science and Technology (the highest award given to Spanish-speaking scientists). In 2008, Dr. Fuster received the Kurt Polzer Cardiovascular Award from the European Academy of Science and Arts. In March 2009, he received the Distinguished Teacher Award of the American College of Cardiology.

After receiving his medical degree from Barcelona University and completing an internship at Hospital Clinic in Barcelona, Dr. Fuster spent several years at the Mayo Clinic, first as a resident and later as Professor of Medicine and Consultant in Cardiology. In 1981, he came to Mount Sinai School of Medicine as head of Cardiology. From 1991 to 1994, he was Mallinckrodt Professor of Medicine at Harvard Medical School and Chief of Cardiology at the Massachusetts General Hospital. He returned to Mount Sinai in 1994 as Director of the Zena and Michael A. Wiener Cardiovascular Institute and most recently, he has been named the Director of the Mount Sinai Heart.

2007 Prize Winner

Patrick W. Serruys

Dr. Serruys received the M.D. degree (1972) from the Catholic University of Louvain, Louvain, Belgium and his PhD degree (1986) from the Erasmus University, Rotterdam, The Netherlands. Patrick W. Serruys is Professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998), and the Erasmus University.

Since 1980 he has been Director of the Clinical Research Program of the Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands and since 1997 the Head of the Interventional Department, Heartcenter Rotterdam. He is a Fellow of the American College of Cardiology and a Fellow of the European Society of Cardiology and scientific council of the International College of Angiology. He is the author or coauthor of over 1400 papers and editor or coeditor of 32 books, and a member of 14 Editorial Boards of Scientific Journals. He has been associate editor of Circulation for Europe for five years and he recently co-edited the Textbook of Cardiology of the European Society of Cardiology.

In 1996 he received the TCT Career Achievement Award and in 1997 he was awarded the Wenkebach Prize of the Dutch Heart Foundation. In 2000 he was awarded the Gruentzig Award of the European Society of Cardiology. In 2001 he held the Paul Dudley White Lecture at the American Heart Association in the USA. In 2004 he held the 4th International Lecture at the AHA and Mikamo Lecture at the Japanese heart Association. In 2006 he received the highest award of the Clinical Council of the American Heart Association: the James Herrick Award.

Summary of Achievements

Patrick Washington Serruys was born on April 27, 1947 (current age 63 years) in Belgium. He graduated from the University of Leuven (MD 1972) and was trained in Cardiology at the same hospital. In 1976 doctor Serruys moved to the Thoraxcenter Erasmus University Rotterdam, which was led at that time by Paul Hugenholtz. He was appointed senior cardiology staff member in 1977 and became director of the clinical research programme in diagnostic and interventional cardiology in 1980. In 1986 he obtained his PhD-degree (cum laude) after defending his thesis on « transluminal coronary angioplasty : an investigational tool of acute myocardial ischemia ». In 1988 doctor Serruys was appointed as Professor of Interventional Cardiology at Erasmus University in Rotterdam and the Inter Cardiology Institute of the Netherlands (ICIN), an institute of the Royal Netherlands Academy of Science (KNAW). Today, professor Serruys is the director of Interventional Cardiology at the Thoraxcenter, Erasmus University Medical Center.

Professor Serruys is fellow, member and/or honorary member of a number of medical organisations and societies, including the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. He has been associate editor of Circulation (2001- 2004) and is a member of the editorial boards of 14 scientific journals. In 2002 he was invited to edit a textbook of cardiology, which will be published by the European Society of Cardiology in the second half of 2005. He has received six significant international awards: the Career Achievement Award (TCT Washington 1996), the Wenckebach Price from the Dutch Heart Foundation (1997), the Andreas Gruentzig Award (European Society of Cardiology, 2000), the Kurt Polzer Price (Austria, 2001), and the Paul Dudley White Award from the American Heart Association (2001).

The research interests of professor Serruys are coronary artery disease and interventional cardiology, ranging from basic science to clinical trials. He has used clinical investigation and interventions as a method for research of coronary pathology and pathophysiology, employing different imaging and measurement techniques including quantitative coronary angiography, intravascular ultrasound, Doppler flow measurements, and more recently palpography as well as optical coherence tomography. Recently a combination of intracoronary imaging and proteomic research has led to increased insight in the pathophysiology of the vulnerable plaque.

Three major developments in interventional cardiology can largely be attributed to Patrick Serruys. First, in the early years of interventional cardiology (1984) he has described the process of restenosis, using a systematic quantitative approach. He systematically studied by quantitative angiography patients at different intervals after balloon angioplasty, and concluded that the restenosis process appeared between 2 and 4 months after the intervention. Therefore, quantitative angiography after 6 months became the world standard for studies of the restenosis process, and of interventions to reduce restenosis. In different animal models, different drugs seemed to be effective to reduce the restenosis process. However, clinical trials, part of which were led by professor Serruys failed to show a systematic reduction of restenosis by antithrombotic therapy, inflammatory therapy, ACE inhibitors and other medication.

Second, professor Serruys was the initiator of the first study comparing stents with balloon angioplasty (Benestent I) and subsequent studies with improved stent design (Benestent II). These studies demonstrated a significant reduction in restenosis using stents. Together with a parallel study in the USA this resulted in the general application of stents in clinical practice, and approval by the regulator authorities (FDA).

Third, in 2000, a new concept has been introduced: drug-eluting stents. These stents are covered with drugs inhibiting the cell cycle, which are slowly released and prevent proliferation of the intima, which is responsible for restenosis. Professor Serruys was the driving force of the concept of the drug eluting stent, assisted in the preclinicial evaluation, the first in man studies, and initiated clinical trials to test the concept. These trials demonstrated that drug eluting stents almost abolish in stent restenosis.

Over the years, the research led by professor Serruys, has been conducted in collaboration with other academic centers in the Netherlands (Inter University Cardiology Institute of the Netherlands), in Europe and in North and South America. He has established close collaboration with different pharmaceutical and medical device companies. Professor Serruys has coached 38 PhD-students who defended their thesis between 1991 and 2005, 24 of these came from abroad, exemplifying his strong international network of research collaboration.

Since 2002, research conducted at the Thoraxcenter has been brought under the newly established cardiovascular research school at the Erasmus University Rotterdam (CŒUR). In CŒUR research is organised in six teams. Professor Serruys is the leader of theme 4: surgical, interventional and device therapy in cardiovascular diseases. Within this context professor Serruys continues to stimulate and lead preclinical and clinical studies of atherosclerosis, the vulnerable plaque, neoangiogenesis and implantation of stam cells or skeletal muscle cells to improve cardiac function after myocardial function. The multidisciplinary interest of professor Serruys has stimulated several technical innovations and the introduction into clinical practice of different technologies developed by engineers at the Thoraxcenter and other institutions, including quantitative coronary angiography, intravascular ultrasound and elastography. The same multidisciplinary approach is evident from the series of meetings organised in 2003, 2004 and 2005 to coordinate worldwide research on the “vulnerable plaque”.

Professor Serruys has been editor or (co) editor of 32 books and he has published over 1.400 papers (up to end 2005) most in international peer reviewed journals. He has been invited to edit the new prestigious Textbook by the European Society of Cardiology. The scope and quality of these papers is outstanding with 10 original articles in the New England Journal of Medicine, 1 in JAMA, 4 in Lancet, 131 in Circulation, 95 in the European Heart Journal and 73 in the Journal of the American College of Cardiology.

His colleagues have enjoyed working with Professor Serruys at the Thoraxcenter for more than 30 years and to share his enthusiasm and energy. He is indeed a creative, imaginative and visionary scientist, a champion for basic and applied research and an active mentor for fellows in training to become an interventional cardiologist as well as PhD-students. While professor Serruys strives for the best research, and high quality patient care, he also has an enthusiastic and warm personality. Professor Serruys is fluent in French, his native language and he is member honoraire de la Societe Francaise de Cardiologie.

2005 Prize Winner

Leonard A. Cobb, MD, Hemeritus Professor, American College of Cardiology, Seattle WA, USA; Peter J. Schwartz, MD, Professor and Chairman, Department of Cardiology, Policlinico San Matteo IRCCS, Pavia, Italy and Hein J.J. Wellens, MD, Honoré Retired Professor, University of Maastricht; Director of Arrhythmology, Interventional Electrophysiology and Cardiology, University of Maastricht, Maastricht, The Netherlands, were the winners of the 2005 Edition of the Arrigo Recordati International Prize.

2003 Prize Winner

Jay N. Cohn , MD, Professor of Medicine, Cardiovascular Division, Departement of Medicine, University of Minnesota Medical School, Minneapolis and John K. Kjekshus, MD, PhD, Professor of Medicine, Department of Cardiology, Rikshospitalet, University of Oslo, Oslo have been selected by the judging panel as the winners of the 2003 edition of the Prize.

2001 Prize Winner

Giuseppe Mancia, PhD

Giuseppe Mancia is Professor of medicine and chairman of the department of clinical medicine, prevention and applied biotechnologies of the University of Milan – Bicocca. He is also chairman of the department of medicine at the S. Gerardo Hospital, Monza, Milan, Italy.

Giuseppe Mancia has been honored for his scientific contributions many times and was the recipient of the Heymans lecture and award from the International Society of Pharmacology, the International Merck Sharp & Dohme Award from the International Society of Hypertension, and the Folkow award from the European Society of Hypertension.

Professor Mancia is president of the European Society of Hypertension and member of the Executive Scientific Council of the American Society of Hypertension. He is also past-president and secretary of the International Society of Hypertension (ISH) and chairman of the World Health Organization-ISH liaison committee for the guidelines on hypertension.

Giuseppe Mancia’s special research interest concerns pathophysiology, diagnosis and therapy of hypertension, heart failure, coronary and other cardiovascular diseases. His expertise includes ambulatory blood pressure monitoring, neural control of the circulation, large artery mechanics and clinical trials.

In addition to publishing hundreds of scientific papers in peer-reviewed journals and a book on hypertension, Professor Mancia is deputy editor of the Journal of Hypertension, past-editor of various international journals on hypertension, and he serves on the editorial board of more than 30 international journals on cardiology, hypertension and internal medicine.

Professor Mancia graduated from the University of Siena, Medical School where he earned his Ph.D. in Physiology. After graduation he spent 3 years in the United States as a postdoctoral fellow at Mayo Clinic and Foundation, and as a resident in cardiology at Virginia Commonwealth University before being appointed professor of medicine at the University of Milan.

 SOURCE
Advertisements

Read Full Post »


Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

Author: Aviva Lev-Ari, PhD, RN

For a general article on Science and Curation, go to

Science and Curation: the New Practice of Web 2.0

Since 4/2012, Leaders in Pharmaceutical Business Intelligence, is developing an innovative methodology for the facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine. For the methodology to attain this complex goal it is to be dealing with popularization of ORIGINAL Scientific Research via Content Curation of Scientific Research Results by Experts, Authors, Writers using the critical  thinking process of expert interpretation of the original research results. We demonstrate in this article two approaches to the process of reaching that goal successfully.

Editorial Team Members and Five Series of e-Bookd in BioMed

Series A: e-Books on Cardiovascular Diseases

Content Consultant: Justin D Pearlman, MD, PhD, FACC

Volume One: Perspectives on Nitric Oxide

Sr. Editor: Larry Bernstein

Editor: Aviral Vatsa

Content Consultant: Stephen J Williams

available on Kindle Store @ Amazon.com

http://www.amazon.com/dp/B00DINFFYC

Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation

Curators: Justin D Pearlman, Larry H Bernstein, Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Volume Three: Etiologies of CVD: Epigenetics, Genetics & Genomics

Curators: Larry H Bernstein and Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Chapter 1: Genomics and Medicine by Marcus Feldman

Volume Four: Therapeutic Promise: CVD, Regenerative & Translational Medicine

Curators: Larry H Bernstein and Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Volume Five: Pharmaco-Therapies for CVD

Curators: Vivek Lal, Larry H Bernstein and Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Volume Six: Interventional Cardiology and Cardiac Surgery

Curators: Justin D Pearlman, Larry H Bernstein, Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Volume Seven: CVD Imaging for Disease Diagnosis and Guidance of Treatment

Curators: Justin D Pearlman and Aviva Lev-Ari

  • Causes
  • Risks and Biomarkers
  • Therapeutic Implications

Series B: e-Books on Genomics & Medicine

Content Consultant: Larry H Bernstein, MD, FCAP

Volume 1: Genomics and Individualized Medicine

Sr. Editor: Stephen J Williams

Editors: Larry H Bernstein and Aviva Lev-Ari

Volume 2: Methodological Breakthroughs in NGS

Editor: Marcus Feldman

Volume 3: Institutional Leadership in Genomics

Editors: Marcus Feldman and Aviva Lev-Ari 

Series C: e-Books on Cancer & Oncology

Content Consultant: Larry H Bernstein, MD, FCAP

Volume 1: Cancer and Genomics

Sr. Editor: Stephen J Williams

Editors: Ritu Saxena, Tilda Barliya

Volume 2: Immunotherapy in Oncology

Sr. Editor: Stephen J Williams

Editors: Tilda Barliya and Demet Sag

Volume 3: Nanotechnology and Drug Delivery

Editor and Author: Tilda Barliya

Series D: e-Books on BioMedicine

Volume 1: Metabolomics

Sr. Editors: Larry H Bernstein and

Editor: Ritu Saxena 

Volume 2: Infectious Diseases

Editor: TBA

Volume 3: Immunology and Therapeutics

Editor: TBA

Series E: Titles in the Strategic Plan for 2014 – 2015

Volume 1: The Patient’s Voice: Personal Experience with Invasive Medical Procedures

Editor: TBA 

Volume 2: Interviews with Scientific Leaders

Editor: TBA

Volume 3: Infectious Milestones in Physiology – Discoveries in Medicine

Editor: TBA

[affiliate] Dr. Pnina G. Abir-Am, Belmont, MA – Independent AUTHOR, History of Molecular Biology

Dr. Aviva Lev-Ari, Boston, MA – Editor-in-Chief, BioMed Series, Editor – Genomics Volume One

Site Statistics

Date

Views to Date

# of articles

NIH Clicks

Nature Clicks

6/24/2013

199,857

1,034

1,275

661

7/29/2013  217,356  1,138  1,389  705
9/11/2013   238,937  1,202  1,495  735
9/26/2013  249,535  1,221  1,570  759

Date

Views to Date

# of articles

NIH Clicks

Nature Clicks

10/14/2013

260,043

1,252

1,593

781

 

This article has two parts:

Part I: The Curator as a Scientific Content Critique for the Architecture of Knowledge, its meaning and its societal implications.

Part II: Cases in Co-Curation and Scientific Content Critique

In Part I, one curator edifies the e-Reader via his/hers OWN creative mental processes of knowledge synthesis following the creative mental process of analytical critique. The outcome is a new FORM of writing Science and of writing about Science, as well as, a new FORM of framework been created for the organization of the interrelations exposed in the analytical phase of a dialectically generated original synthesis, the process of which is manifold: the structure of the knowledge presented, culling in the midst of inclusion/exclusion dialectics and finally the Curator’s own original synthetic statements of the new Art, a new conceptual perspective on Science.

  • For our VISION, See

https://pharmaceuticalintelligence.com/vision/

  • For periodic updates to the List of Cases developed by this Author/Curator, see

https://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/

  • For a complete contribution to the Open Access Online Scientific Journal by the Author/Curator, see

http://pharmaceuticalintelligence.com — Search by Author/Curator’s Last Name, 567 articles on 7/30/2013

  • For the BioMed e-Books Series in Production, see

https://pharmaceuticalintelligence.com/biomed-e-books/

  • FIRST book of their BioMedical E-Book Series, Perspectives on Nitric Oxide in Disease Mechanisms, now available on Amazon.com Kindle Store

http://www.amazon.com/dp/B00DINFFYC

  • For CV of our entire Team of Experts, Authors, Writers, see

https://pharmaceuticalintelligence.com/contributors-biographies/

In part Part II: Cases in Co-Curation and Scientific Content Critique, are presented. A similar process to the one in Part I, is been applied. However, the Co-Curation, brings on stage several players. The Actors in the Scientific Writers Theater,  all own scientific knowledge and master the process of creation of a new Synthesis for most writing engagements. Since the Co-curators are educated in different disciplines, they are skillfully providing interpretations for others’ and their own new conception of ideas. Thus, they are developing new views of the original scientific results presented in peer reviewed journals, just the leading ones in every field. The Co-Curators, their creation is a new layer of comprehension for the processes at hand.

Example #1:

Action Potential, a well define concept in Physiology. For us,  Action Potential was a conceptual creation for the process of Co-Curation. Dr. Lev-Ari, requesting Dr. Bernstein to elaborate creatively, on the function of actin in cytoskeleton mobility, he did,  THEN a new conceptual creation process emerged and had YIELDED the following article:

Identification of Biomarkers that are Related to the Actin Cytoskeleton

Curator: Larry H Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2012/12/10/identification-of-biomarkers-that-are-related-to-the-actin-cytoskeleton/

Example #2:

The e-Reader reads first

High Serum Calcium Linked to Developing Diabetes: IRAS Study

 Sep 24, 2013

http://www.medscape.com/viewarticle/811536

The e-Reader reads second the curation of that Source Interview

Diabetes-risk Forecasts: Serum Calcium in Upper-Normal Range (>2.5 mmol/L) as a New Biomarker

https://pharmaceuticalintelligence.com/2013/09/25/diabetes-risk-forecasts-serum-calcium-in-upper-normal-range-2-5-mmoll-as-a-new-biomarker/

The e-Reader will compare which of the two is more beneficial for the e-Reader.

We believe that the curation of the Source Interview has remarkable value added analysis that the Reader can benefit from.

The unique process as described for Part I and for Part II, above, will be demonstrated, below,  in concrete cases, as we applied the methodology of curation by one or by several Experts, Authors, Writers in the field of Cardiovascular Diseases.

The Process: We culled the scene for Cardiovascular Original Research in +24 Journals, we pre-select domains of research to cover: The Etiology of the Disease, the Risks of dysfunction at cellular, tissue, organelle, organ, anatomy, physiology, pathophysiology and diagnostics for all of the above. We interpret the Disease Management Options in a comprehensive fashion, exposing the e-Reader to an integrative approach for the treatment of Cardiovascular Disease.

Below,  the e-Reader finds selective cases exemplifying the methodology described, making

the one and only on the Internet and in e-Book Stores, to date.

 

Part I       

The Curator as a Scientific Content Critique for the Architecture of Knowledge

Lev-Ari, A. 8/6/2013 Stent Design and Thrombosis:  Bifurcation Intervention, Drug Eluting Stents (DES) and Biodegrable Stents

https://pharmaceuticalintelligence.com/2013/08/06/stent-design-and-thrombosis-bifurcation-intervention-drug-eluting-stents-des-and-biodegrable-stents/

Lev-Ari, A. 8/1/2013 Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD

https://pharmaceuticalintelligence.com/2013/08/01/calcium-molecule-in-cardiac-gene-therapy-inhalable-gene-therapy-for-pulmonary-arterial-hypertension-and-percutaneous-intra-coronary-artery-infusion-for-heart-failure-contributions-by-roger-j-hajjar/

Lev-Ari, A. 7/19/2013 3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy

https://pharmaceuticalintelligence.com/2013/07/19/3d-cardiovascular-theater-hybrid-cath-labor-suite-hybrid-surgery-complications-post-pci-and-repeat-sternotomy/

Lev-Ari, A. 7/14/2013 Vascular Surgery: International, Multispecialty Position Statement on Carotid Stenting, 2013 and Contributions of a Vascular Surgeon at Peak Career – Richard Paul Cambria, MD

https://pharmaceuticalintelligence.com/2013/07/14/vascular-surgery-position-statement-in-2013-and-contributions-of-a-vascular-surgeon-at-peak-career-richard-paul-cambria-md-chief-division-of-vascular-and-endovascular-surgery-co-director-thoracic/

Lev-Ari, A. 7/9/2013 Heart Transplant (HT) Indication for Heart Failure (HF): Procedure Outcomes and Research on HF, HT @ Two Nation’s Leading HF & HT Centers

https://pharmaceuticalintelligence.com/2013/07/09/research-programs-george-m-linda-h-kaufman-center-for-heart-failure-cleveland-clinic/

Lev-Ari, A. 7/8/2013 Becoming a Cardiothoracic Surgeon: An Emerging Profile in the Surgery Theater and through Scientific Publications

https://pharmaceuticalintelligence.com/2013/07/08/becoming-a-cardiothoracic-surgeon-an-emerging-profile-in-the-surgery-theater-and-through-scientific-publications/

Lev-Ari, A. 7/1/22013 Endovascular Lower-extremity Revascularization Effectiveness: Vascular Surgeons (VSs), Interventional Cardiologists (ICs) and Interventional Radiologists (IRs)

https://pharmaceuticalintelligence.com/2013/07/01/endovascular-lower-extremity-revascularization-effectiveness-vascular-surgeons-vss-interventional-cardiologists-ics-and-interventional-radiologists-irs/

Lev-Ari, A. 6/10/2013 No Early Symptoms – An Aortic Aneurysm Before It Ruptures – Is There A Way To Know If I Have it?

https://pharmaceuticalintelligence.com/2013/06/10/no-early-symptoms-an-aortic-aneurysm-before-it-ruptures-is-there-a-way-to-know-if-i-have-it/

Lev-Ari, A. 6/9/2013 Congenital Heart Disease (CHD) at Birth and into Adulthood: The Role of Spontaneous Mutations

https://pharmaceuticalintelligence.com/2013/06/09/congenital-heart-disease-at-birth-and-into-adulthood-the-role-of-spontaneous-mutations-the-genes-and-the-pathways/

Lev-Ari, A. 6/3/2013 Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

https://pharmaceuticalintelligence.com/2013/06/03/clinical-indications-for-use-of-inhaled-nitric-oxide-ino-in-the-adult-patient-market-clinical-outcomes-after-use-therapy-demand-and-cost-of-care/

Lev-Ari, A. 6/2/2013 Inhaled Nitric Oxide in Adults: Clinical Trials and Meta Analysis Studies – Recent Findings

https://pharmaceuticalintelligence.com/2013/06/02/inhaled-nitric-oxide-in-adults-with-acute-respiratory-distress-syndrome/

Lev-Ari, A. 5/17/2013 Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

https://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Lev-Ari, A. 4/28/2013 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

https://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

Lev-Ari, A. 2/28/2013 The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN

https://pharmaceuticalintelligence.com/2013/02/28/the-heart-vasculature-protection-a-concept-based-pharmacological-therapy-including-thymosin/

Part II         

Cases in Co-Curation and Scientific Content Critique

Pearlman, JD, and A.  Lev-Ari, 9/30/2013

State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine(TM)

https://pharmaceuticalintelligence.com/2013/09/30/state-of-cardiology-on-wall-stress-ventricular-workload-and-myocardial-contractile-reserve-aspects-of-translational-medicine/

Lal, V, Pearlman JD, and A. Lev-Ari, 9/23/2013

Do Novel Anticoagulants Affect the PT/INR? The Cases of  XARELTO (rivaroxaban) or PRADAXA (dabigatran)

https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/

Bernstein LH, SJ Williams and A. Lev-Ari, 8/26/2013

Part II: Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility

https://pharmaceuticalintelligence.com/2013/08/26/role-of-calcium-the-actin-skeleton-and-lipid-structures-in-signaling-and-cell-motility/

Bernstein LH, SJ Williams and A. Lev-Ari,  9/2/2013

Part III: Renal Distal Tubular Ca2+ Exchange Mechanism in Health and Disease

https://pharmaceuticalintelligence.com/2013/09/02/renal-distal-tubular-ca2-exchange-mechanism-in-health-and-disease/

Bernstein LH, Pearlman JD and A. Lev-Ari, 9/8/2013

Part IV: The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets

https://pharmaceuticalintelligence.com/2013/09/08/the-centrality-of-ca2-signaling-and-cytoskeleton-involving-calmodulin-kinases-and-ryanodine-receptors-in-cardiac-failure-arterial-smooth-muscle-post-ischemic-arrhythmia-similarities-and-differen/

Bernstein LH, Pearlman JD and A. Lev-Ari, 8/26/2013

Part V: Heart, Vascular Smooth Muscle, Excitation-Contraction Coupling (E-CC), Cytoskeleton, Cellular Dynamics and Ca2 Signaling

https://pharmaceuticalintelligence.com/2013/08/26/heart-smooth-muscle-excitation-contraction-coupling-cytoskeleton-cellular-dynamics-and-ca2-signaling/

Pearlman, JD, Bernstein, HL and A. Lev-Ari 8/28/2013

Part VII: Cardiac Contractility & Myocardium Performance: Ventricular Arrhythmias and Non-ischemic Heart Failure – Therapeutic Implications for Cardiomyocyte Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses

https://pharmaceuticalintelligence.com/2013/08/28/cardiac-contractility-myocardium-performance-ventricular-arrhythmias-and-non-ischemic-heart-failure-therapeutic-implications-for-cardiomyocyte-ryanopathy-calcium-release-related-contractile/

Pearlman, JD, Bernstein, LH and A. Lev-Ari, 9/12/2013

Part VIII: Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism

https://pharmaceuticalintelligence.com/2013/09/12/disruption-of-calcium-homeostasis-cardiomyocytes-and-vascular-smooth-muscle-cells-the-cardiac-and-cardiovascular-calcium-signaling-mechanism/

Pearlman, JD, Bernstein, LH and A. Lev-Ari, 9/16/2013

Part IX: Calcium-Channel Blockers, Calcium Release-related Contractile Dysfunction (Ryanopathy) and Calcium as Neurotransmitter Sensor

https://pharmaceuticalintelligence.com/2013/09/16/calcium-channel-blocker-calcium-as-neurotransmitter-sensor-and-calcium-release-related-contractile-dysfunction-ryanopathy/

Bernstein, LH and A. Lev-Ari, 9/10/2013

Part X: Synaptotagmin functions as a Calcium Sensor: How Calcium Ions Regulate the fusion of vesicles with cell membranes during Neurotransmission

https://pharmaceuticalintelligence.com/2013/09/10/synaptotagmin-functions-as-a-calcium-sensor-how-calcium-ions-regulate-the-fusion-of-vesicles-with-cell-membranes-during-neurotransmission/

Pearlman JD and A. Lev-Ari 8/25/2013

Coronary Circulation Combined Assessment: Optical Coherence Tomography (OCT), Near-Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) – Detection of Lipid-Rich Plaque and Prevention of Acute Coronary Syndrome (ACS)

https://pharmaceuticalintelligence.com/2013/08/25/coronary-circulation-combined-assessment-optical-coherence-tomography-oct-near-infrared-spectroscopy-nirs-and-intravascular-ultrasound-ivus-detection-of-lipid-rich-plaque-and-prevention-of-a/

Pearlman, JD, Bernstein, LH and A. Lev-Ari 8/5/2013

Alternative Designs for the Human Artificial Heart: The Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community. To be submitted to Heart Failure Society of America (HFSA)

https://pharmaceuticalintelligence.com/2013/08/05/alternative-designs-for-the-human-artificial-heart-the-patients-in-heart-failure-outcomes-of-transplant-donorimplantation-artificial-and-monitoring-technologies-for-the-transplantimplant-pat/

Pearlman, JD and A. Lev-Ari 7/23/2013

Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions

https://pharmaceuticalintelligence.com/2013/07/23/cardiovascular-complications-of-multiple-etiologies-repeat-sternotomy-post-cabg-or-avr-post-pci-pad-endoscopy-andor-resultant-of-systemic-sepsis/

Pearlman, JD and A. Lev-Ari 7/22/2013

Cardiac Resynchronization Therapy (CRT) to Arrhythmias: Pacemaker/Implantable Cardioverter Defibrillator (ICD) Insertion

https://pharmaceuticalintelligence.com/2013/07/22/cardiac-resynchronization-therapy-crt-to-arrhythmias-pacemakerimplantable-cardioverter-defibrillator-icd-insertion

Pearlman, JD and A. Lev-Ari 7/17/2013

Emerging Clinical Applications for Cardiac CT: Plaque Characterization, SPECT Functionality, Angiogram’s and Non-Invasive FFR

https://pharmaceuticalintelligence.com/2013/07/17/emerging-clinical-applications-for-cardiac-ct-plaque-characterization-spect-functionality-angiograms-and-non-invasive-ffr/

Pearlman, JD and A. Lev-Ari 7/4/2013

Fractional Flow Reserve (FFR) & Instantaneous wave-free ratio (iFR): An Evaluation of Catheterization Lab Tools for Ischemic Assessment

https://pharmaceuticalintelligence.com/2013/07/04/fractional-flow-reserve-ffr-instantaneous-wave-free-rario-ifr-an-evaluation-of-catheterization-lab-tools-for-ischemic-assessment/

Pearlman, JD and A. Lev-Ari 5/24/2013

Imaging Biomarker for Arterial Stiffness: Pathways in Pharmacotherapy for Hypertension and Hypercholesterolemia Management

https://pharmaceuticalintelligence.com/2013/05/24/imaging-biomarker-for-arterial-stiffness-pathways-in-pharmacotherapy-for-hypertension-and-hypercholesterolemia-management/

Pearlman, JD and A. Lev-Ari 5/22/2013

Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone

https://pharmaceuticalintelligence.com/2013/05/22/acute-and-chronic-myocardial-infarction-quantification-of-myocardial-viability-fdg-petmri-vs-mri-or-pet-alone/

Pearlman JD, LH Bernstein and A. Lev-Ari 5/15/2013

Diagnosis of Cardiovascular Disease, Treatment and Prevention: Current & Predicted Cost of Care and the Promise of Individualized Medicine Using Clinical Decision Support Systems

https://pharmaceuticalintelligence.com/2013/05/15/diagnosis-of-cardiovascular-disease-treatment-and-prevention-current-predicted-cost-of-care-and-the-promise-of-individualized-medicine-using-clinical-decision-support-systems-2/

Pearlman, JD and A. Lev-Ari 5/11/2013

Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

https://pharmaceuticalintelligence.com/2013/05/11/arterial-elasticity-in-quest-for-a-drug-stabilizer-isolated-systolic-hypertension-caused-by-arterial-stiffening-ineffectively-treated-by-vasodilatation-antihypertensives/

Pearlman, JD and A. Lev-Ari 5/7/2013

On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

https://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/

Pearlman, JD and A. Lev-Ari 5/4/2013

Clinical Decision Support Systems for Management Decision Making of Cardiovascular Diseases

https://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/

Lev-Ari, A. and LH Bernstein 3/7/2013

Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

https://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

Find out more:

« Curation is the new research, »… et le nouveau média, Benoit Raphael, 2011http://benoitraphael.com/2011/01/17/curation-is-the-new-search/

La curation : la révolution du webjournalisme?, non-fiction.fr http://www.nonfiction.fr/article-4158-la_curation__la_revolution_du_webjournalisme_.htm

La curation : les 10 raisons de s’y intéresser, Pierre Tran http://pro.01net.com/editorial/529947/la-curation-les-10-raisons-de-sy-interesser/

Curation : quelle valeur pour les entreprises, les médias, et sa « marque personnelle »?, Marie-Laure Vie http://marilor.posterous.com/curation-et-marketing-de-linformation

Cracking Open the Scientific Process, Thomas Lin, New York Timeshttp://www.nytimes.com/2012/01/17/science/open-science-challenges-journal-tradition-with-web-collaboration.html?_r=4&pagewanted=1

La « massification » du web transforme les relations sociales, Valérie Varandat, INRIAhttp://www.inria.fr/actualite/actualites-inria/internet-du-futur

Internet a révolutionné le métier de chercheur, AgoraVoxhttp://www.agoravox.fr/actualites/technologies/article/internet-a-revolutionne-le-metier-103514

Gérer ses références numériques, Université de Genèvehttp://www.unige.ch/medecine/udrem/Unit/actualites/biblioManager.html

Notre liste Scoop-it : Scientific Social Network, MyScienceWork

SOURCE on Curation and Science

Share this:

 

Read Full Post »


Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer

Curator and Reporter: Stephen J. Williams, PhD

This is the second posting in this series in which I highlight the basic research which led to seminal breakthroughs in the medical field, brought on by the result of basic inquiry, thorough and detailed investigation, meticulously following the scientific method, and eventually leading to development of important medical therapies.

In his autobiography, Virus Hunting: AIDS, Cancer & the Human Retrovirus: A Story of Scientific Discovery, Dr. Robert Gallo, M.D. describes a wonderful story of the history behind, scientific biographies, and chronology of the discoveries which led he and his colleagues (including co-discoverer Dr. Luke Montagnier) to recognize retroviruses (in particular HIV) as the leading culprit for the cause of AIDS and in the etiology of Kaposi’s sarcoma.   For anyone who appreciates the history behind scientific discoveries and appreciates learning about the multitude of individual efforts which are the crux of seminal research, this book is a must read.

Recommendations from the back cover include:

Virus Hunting will be read and reread, for years to come.” —New York Newsday

“Provides a human, revealing look into the arcane, usually secret confines of laboratory science.”

Martin Delany, Project Inform

..as well as others.

While a fascinating aspect of this book is the description, like fitting pieces of a puzzle, of the important discoveries throughout history which are the necessary foundations for further investigations and discoveries, more important is a telling, personal narrative of the people involved in those initial and subsequent discoveries.  In fact, the book has over 396 colleagues, mentors, technicians, students, and even critiques who are given credit, in one form or another, for the ultimate discovery of HIV as a causative agent for the development of AIDS. The book is a literal Who’s Who in Science and shows how important personal collaboration and friendships are in the process of scientific discovery.

In 1972, Dr. Seymour Perry had appointed the young Dr. Robert Gallo as head of a new department, the Human Tumor Cell Biology Branch, renamed the Laboratory of Tumor Cell Biology.  The lab was carrying on the work on tRNA that Dr. Gallo had performed in Dr. Sid Perska’s group at NIH.  However, with the help of new lab members Dr. David Gillespie, Dr. Flossie Wong-Staal, and Dr. Marjorie Robert-Guroff the lab focused on the search for disease-causing retroviruses, especially in human leukemias.  This was, in part, due to conversations with Dr. Robert Huebner and Todaro, who insisted that

“within the genetic makeup of this endogenous retroviral material was, they suggested, a special gene, the oncogene, that was the parent of the cancer-causing protein”

which may explain some of the early work by Rous concerning the Rous sarcoma virus.

Enter in Gallo’s good friend Dr. Bob Ting.  Dr. Gallo had known Dr. Ting socially since 1966, shortly after Gallo had arrived at NIH.  Dr. Bob Ting was a well-established NCI investigator, who was doing work on DNA and RNA oncogenic viruses of animals.  Originally from a large and wealthy family in Hong Kong, Dr. Ting had worked with Nobel Prize winners Salvatore Luria (who worked on phages) and Renato Dulbecco, who, along with his well-known cell culture media, had made the seminal discoveries that led to our knowledge how some DNA viruses can transform normal animal cells into neoplastic-like cells in culture.

Bob Ting gave a talk on these oncogenic viruses and Gallo was very interested in his observations that oncogenic viruses like Rous and Maloney, could transform cells in vitro in a matter of days.

A friendship developed between the two over tennis matches and Chinese food.  During this time, Dr. Ting made the important suggestion that they both collaborate and use the viral systems developed by Dulbecco.  Ting also introduced him to RNA viruses, Dr. Robert Huebner, and Dr. Howard Temin.  It was, in part, due to these associations that Gallo started looking, in earnest, at the possibility of RNA retroviruses in leukemias. Thus, just like the internet today, connections and networking provided new insights into current research, and helped lead the advent of new discoveries, therapies, and scientific disciplines.

Therefore, “after some late-night discussion with Bob Ting, I decided to enter the fray. My own laboratory, … would immediately be set up to compare the properties of reverse transcriptase enzymes from many different animal retroviruses”.

Although the rest is more history, this early friendship, collaboration, and mentoring by Bob Ting had “transformed” Gallo’s research efforts to set him up to make some of the important discoveries eventually leading to the discovery of the role of HIV in AIDS.

A video interviewing Dr. Gallo can be found here:

VIEW VIDEO

https://www.youtube.com/watch?v=ELRlXLGWu4I

A very nice writeup/obituary for Dr. Ting was written by Patricia Sullivan of the Washington Post and is included below.

Robert Ting, 77; Biotech Pioneer

ME/Ting-ob

Dr. Robert Ting’s biotech company in Rockville developed the first FDA-approved diagnostic test kits to test for HIV antibodies. (By Gerald Martineau — The Washington Post)

 

By Patricia Sullivan

Washington Post Staff Writer
Friday, September 22, 2006

Robert C.Y. Ting, 77, a research scientist who started one of the early biotechnology companies in the Washington area, died Sept. 11 of complications after cardiac surgery at the Cleveland Clinic in Cleveland.

Dr. Ting founded Biotech Research Laboratories Inc. in Rockville in 1973, producing cells for government scientists to use in research. Eleven years later, his firm obtained a federal license to develop and produce the first FDA-approved diagnostic test kits for HIV antibody confirmation.

Robert C. Gallo, who co-discovered the HIV virus as the cause of AIDS, called Dr. Ting a pioneer in the field who popularized the term “biotechnology” when he moved from research to entrepreneurship.

“He introduced me to virology, and he did it twice,” said Gallo, director of the Institute of Human Virology in Baltimore. The men had known each other since the 1960s, and while playing tennis one day, Dr. Ting advised the cancer researcher to look at new research in viruses. Later, when Gallo was studying leukemia, Dr. Ting directed him to animal research in leukemia. “First he showed me how viruses change cells. Then he introduced me to retrovirology. . . . I went into retrovirology solely because of those discussions with Bob Ting on tennis courts,” Gallo said.

Dr. Ting, whom Gallo described as a quiet, modest man, was born in Shanghai, the son of a physician to Gen. Chiang Kai-Shek. His family fled the country during the Japanese invasion of China during World War II and moved to Hong Kong. Soon after, he moved to the United States, where he received a bachelor’s degree and in 1956 a master’s degree in genetics from Amherst College.

He received a doctoral degree in microbiology and biochemistry from the University of Illinois in 1960 under Salvador E. Luria, who later won the 1969 Nobel Prize in Medicine and Physiology. Dr. Ting spent the next two years on a postdoctoral fellowship at the California Institute of Technology, working with Renato Dulbecco, who later won the 1975 Nobel Prize in Medicine and Physiology. Their work focused on how viruses cause tumors.

“A lot of molecular biology developed from this,” Dr. Ting told The Washington Post in 1984 from his Rockville office, cluttered with scientific journals, awards and a large blackboard. “There was so much evidence in animal systems [that viruses cause tumors], that the next question was obvious — can you find the equivalent in humans.”

Dr. Ting joined the National Institutes of Health in 1962 as a visiting fellow and then a senior research scientist at the National Cancer Institute. From 1966 to 1968, he was an associate editor for the Journal of the National Cancer Institute.

In 1969, he joined Litton Bionetics Inc. in Rockville as director of experimental oncology, leading a project funded by the institute to search for viruses in human leukemia patients. He became scientific director of the cancer research branch the next year.

With academic, government and private business experience under his belt, Dr. Ting decided to go into business on his own and in 1973 started Biotech Research Laboratories in Rockville. It was a profitable supplier of research services and supplies until 1981, when it went public and produced the HIV diagnostic test kits. It became one of the most successful public biotech companies in the area in the mid-1980s.

The Economic Development Board of Singapore invited him to return to Asia to start a biotech company, which he did in 1985, forming Diagnostic Biotechnology Ltd. He also joined the Institute of Molecular and Cell Biology at the National University of Singapore, which Gallo called “the most prominent Asian academic biotechnology center.”

He returned to the United States in 1998 to join the board of Cell Works Inc. in Baltimore, and became chair and chief executive of a joint venture, Cell Works Asia Limited, in 2000.

Most recently, Dr. Ting was the founding president and chief executive of Profectus Biosciences Inc. of Baltimore, previously known as Maryland BioTherapeutics Inc.

Dr. Ting was past chairman of the F.F. Fraternity, one of the oldest Chinese fraternities in the United States. He was also a member of the Organization of Chinese Americans in the D.C. area since its inception in the early 1970s. He enjoyed tennis, golf, ballroom dancing and international travel. He also was a wine connoisseur.

Survivors include his wife of 44 years, Sylvia Han Ting of Potomac; three children, Anthony Ting of Shaker Heights, Ohio, Andrew Ting of Beverly, Mass., and Jennifer Chow of Potomac; seven sisters; and seven grandchildren.

An obituary written from his son Anthony can be found here:

https://www.amherst.edu/aboutamherst/magazine/in_memory/1953/robertting

Sources:

http://www.amazon.com/Virus-Hunting-Retrovirus-Scientific-Discovery/dp/0465098150

http://www.washingtonpost.com/wp-dyn/content/article/2006/09/21/AR2006092101936.html

Other articles/postings related to this topic and HIV on this site includes:

Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin

History of medicine, science, and society: 200 Years of the New England Journal of Medicine

Why did Pauling Lose the “Race” to James Watson and Francis Crick? How Crick Describes his Discovery in a Letter to his Son

John Randall’s MRC Research Unit and Rosalind Franklin’s role at Kings College

Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin

Otto Warburg, A Giant of Modern Cellular Biology

Inspiration From Dr. Maureen Cronin’s Achievements in Applying Genomic Sequencing to Cancer Diagnostics

Nanotechnology and HIV/AIDS treatment

HIV vaccine: Caltech puts us One step further

Getting Better: Documentary Videos on Medical Progress — in Surgery, Leukemia, and HIV/AIDS.

Read Full Post »


e-Recognition via Friction-free Collaboration over the Internet: “Open Access to Curation of Scientific Research”

Curator: Aviva Lev-Ari, PhD, RN

Journal Site Statistics UPDATED on 7/22/2014

Scientific Journal Site Statistics

http://pharmaceuticalintelligence.com

 

415,392 Views

2,093 Posts

241 Categories

6,066 Tags

6,755 Comments

 

Referrer Views
Search Engines 175,831
linkedin.com 14,321
Facebook 3,586
Twitter 1,223
investorshub.advfn.com 1,058

 

 

 3/05/2014  338,938  1,717  1,830  965

Date

Views to Date

# of articles

NIH Clicks

Nature Clicks

6/24/2013

 199,857

 1,034

 1,275

 661

 7/29/2013  217,356  1,138  1,389  705
 12/1/2013  287,645  1,428  1,676  828
 2/09/2014  325,039  1,665  1,793  892
 7/22/2014  415,392  2,093  2,014  1,132

Top Authors for all days ending 2014-03-05 (Summarized)

AUTHOR ID

VIEWS

Aviva Lev-Ari, PhD, RN [2012pharmaceutical]

131,222

larryhbern

59,751

tildabarliya

22,372

Dr. Sudipta Saha

14,737

Dror Nir

11,550

sjwilliamspa

12,059

ritusaxena

10,210

aviralvatsa

5,428

zraviv06

3,170

Demet Sag, Ph.D., CRA, GCP

3,741

anamikasarkar

2,360

pkandala

1,908

zs22

1,895

Alan F. Kaul, PharmD., MS, MBA, FCCP

1,420

megbaker58

1,107

Aashir Awan, Phd

945

jdpmdphd

569

UPDATED on 10/14/2013 

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

UPDATED on 4/8/2013

This article has three parts.

Part 1,  presents a pioneering experience in Curation of Scientific Research of three forms:

Part 2, presents Views of two Curators on the transformation of Scientific Publishing and the functioning of the Scientific AGORA (market place in the Ancient Greek CIty of Athena).

Part 3, presents the

“Beall’s list” a blacklist of “predatory” journals: Scientific Articles to be Accepted for Publications followed by a Bill to Pay for been Published

Part One

e-Recognition for Author Views is presented below of a pioneering launch of the ONE and ONLY web-based Open Access Online Scientific Journal on frontiers in Biomedical Technologies, Genomics, Biological SciencesHealthcare Economics, Pharmacology, Pharmaceutical & Medicine.

Friction-free Collaboration over the Internet: An Equity Sharing Venture for “Open Access to Curation of Scientific Research” launched THREE TYPES of Scientific Research Sharing

Type 1:

“Open Access to Curation of Scientific Research – Online Scientific Journal

 http://pharmaceuticalintelligence.com

The venture, Leaders in Pharmaceutical Business Intelligence, operates as an online scientific intellectual EXCHANGE – an Open Access Online Scientific Journal for curation and reporting on frontiers in Biomedical, Genomics, Biological SciencesHealthcare Economics, Pharmacology, Pharmaceutical & Medicine. The website,  http://pharmaceuticalintelligence.com , is a scientific, medical and business multi expert authoring environment  in several domains of  LIFE SCIENCES, PHARMACEUTICAL, HEALTHCARE & MEDICINE INDUSTRIES.

https://pharmaceuticalintelligence.com/open-access-scientific-journal/about/

https://pharmaceuticalintelligence.com/contributors-biographies/

https://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/

Our organic in growth ONTOLOGY includes ~ 90 Research Categories, i.e.,

  •  Advanced Drug Manufacturing Technology
  •  Alzheimer’s Disease
    •  Etiology
    •  Medical Device Therapies for Altzheimer’s disease
    •  Pharmacotherapy
  •  Bio Instrumentation in Experimental Life Sciences Research
  •  Biological Networks, Gene Regulation and Evolution
  •  Biomarkers & Medical Diagnostics
  •  BioSimilars
  •  Bone Disease and Musculoskeletal Disease
  •  CANCER BIOLOGY & Innovations in Cancer Therapy
  •  Cancer Prevention: Research & Programs
  •  Cardiovascular Pharmaceutical Genomics
  •  Cell Biology, Signaling & Cell Circuits
  •  Cerebrovascular and Neurodegenerative Diseases
  •  Chemical Biology and its relations to Metabolic Disease
  •  Chemical Genetics
  •  Coagulation Therapy and Internal Bleeding
  •  Computational Biology/Systems and Bioinformatics
  •  Disease Biology, Small Molecules in Development of Therapeutic Drugs
  •  Drug Delivery Platform Technology
  •  Ecosystems & Industrial Concentration in the Medical Device Sector
    •  Cardiac & Vascular Repair Tools Subsegment
    •  Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment
    •  Massachusetts Niche Suppliers and National Leaders
  •  FDA Regulatory Affairs
    •  FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155
    •  ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics
  •  Frontiers in Cardiology
    •  Medical Devices
      •  Stents & Tools
      •  Valves & Tools
    •  Pharmacotherapy of Cardiovascular Disease
      •  HTN
      •  HTN in Youth
      •  Resident-cell-based
    •  Procedures
      •  Aortic Valve: TAVI, TAVI vs Open Heart Surgery
      •  CABG
      •  Mitral Valve: Repair and Replacement
      •  PCI
      •  Renal Denervation
  •  Genome Biology
  •  Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics
  •  Genomic Testing: Methodology for Diagnosis
  •  Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics
  •  Health Economics and Outcomes Research
  •  Health Law & Patient Safety
  •  HealthCare IT
  •  Human Immune System in Health and in Disease
  •  Human Sensation and Cellular Transduction: Physiology and Therapeutics
  •  Imaging-based Cancer Patient Management
  •  Infectious Disease & New Antibiotic Targets
  •  Innovations in Neurophysiology & Neuropsychology
  •  International Global Work in Pharmaceutical
  •  Interviews with Scientific Leaders
  •  Liver & Digestive Diseases Research
  •  Medical and Population Genetics
  •  Medical Devices R&D Investment
  •  Medical Imaging Technology, Image Processing/Computing, MRI
  •  Metabolomics
  •  Molecular Genetics & Pharmaceutical
  •  Nanotechnology for Drug Delivery
  •  Nitric Oxide in Health and Disease
  •  Nutrigenomics
  •  Nutrition
    •  Nutritional Supplements: Atherogenesis, lipid metabolism
  •  Origins of Cardiovascular Disease
    •  Atherogenic Processes & Pathology
  •  Pain: Etiology, Genetics & Innovations in Treatment
  •  Patient Experience: Personal Memories of Invasive Medical Intervantion
  •  Personalized Medicine & Genomic Research
  •  Pharmaceutical Analytics
  •  Pharmaceutical Industry Competitive Intelligence
  •  Pharmaceutical R&D Investment
  •  Pharmacogenomics
  •  Population Health Management, Genetics & Pharmaceutical
  •  Population Health Management, Nutrition and Phytochemistry
  •  Proteomics
  •  Regulated Clinical Trials: Design, Methods, Components and IRB related issues
  •  Reproductive Biology & Bio Instrumentation
  •  Scientist: Career considerations
  •  Statistical Methods for Research Evaluation
  •  Stem Cells for Regenerative Medicine
  •  Systemic Inflammatory Response Related Disorders
  •  Technology Transfer: Biotech and Pharmaceutical

Open Access Online Scientific Journal Site Statistics: Site Launched in February 2012, first post Published on 4/30/2012

https://pharmaceuticalintelligence.com/2012/04/30/93/

On 4/2/2013, less then one year since the first post was published as a CURATED article, we achieved the following results:

150,339 Views

766 Posts

87 Categories

3,908 Tags

3,706 Comments

Referrer Views
Search Engines 43,238
linkedin.com 9,865
Google 2,171
Facebook 1,591

URL    Clicks

ncbi.nlm.nih.gov    1,014

nature.com    513

genomeweb.com    215

medicregister.com    177

sciencedirect.com    156

pnas.org    145

nejm.org    125

Author        Views

2012pharmaceutical        51,214 <<<<—- Aviva

larryhbern    Following    19,819

tildabarliya        6,924

Dr. Sudipta Saha    Following    6,859

ritusaxena    Following    5,795

Dror Nir    Follow    4,190

sjwilliamspa    Following    3,369

aviralvatsa    Following    3,216

anamikasarkar    Following    1,682

pkandala    Follow    1,595

Alan F. Kaul, PharmD., MS, MBA, FCCP    Following    1,068

megbaker58    Following    826

zs22    Following    444

zraviv06    Following    438

Aashir Awan, Phd    Following    413

howarddonohue    Following    297

Ed Kislauskis    Following    157

Demet Sag    Follow    130

jukkakarjalainen    Follow    130

anayou1    Following    128

jdpmdphd    Follow    124

Dr.Sreedhar Tirunagari    Follow    92

S. Chakrabarti, Ph.D.    Following    49

apreconasia    Follow    43

Most Viewed Posts

Is the Warburg Effect the cause or the effect of cancer: A 21st Century View? More stats 1,945
Perspectives on Nitric Oxide in Disease Mechanisms More stats 1,925
About More stats 1,836
Contributors’ Biographies More stats 1,639
Founder More stats 1,026
Future of Calcitonin…? More stats 854
Treatment of Refractory Hypertension via Percutaneous Renal Denervation More stats 851
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly More stats 835
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers More stats 824
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) More stats 737
Transcatheter Aortic Valve Implantation (TAVI): Risky and Costly More stats 691
Closing the Mammography gap More stats 667
Nitric Oxide has a ubiquitous role in the regulation of glycolysis -with a concomitant influence on mitochondrial function More stats 659
Assessing Cardiovascular Disease with Biomarkers More stats 629
Introduction to Tissue Engineering; Nanotechnology applications More stats 613
Novel Cancer Hypothesis Suggests Antioxidants Are Harmful More stats 602
Paradigm Shift in Human Genomics – Predictive Biomarkers and Personalized Medicine – Part 1 More stats 597
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation More stats 593
DNA – The Next-Generation Storage Media for Digital Information More stats 588
“The Molecular pathology of Breast Cancer Progression” More stats 563
Zithromax – likely to ‘max’ Heart Attack More stats 557
TransCelerate BioPharma Inc. to Accelerate the Development of New Meds More stats 554
Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade More stats 549
Mitochondria: More than just the “powerhouse of the cell” More stats 537
Big Data in Genomic Medicine More stats 531
Get Rid of the Randomized Trial; Here’s a Better Way More stats 522
Biosimilars: CMC Issues and Regulatory Requirements More stats 521
Biosimilars: Financials 2012 vs. 2008 More stats 513
New England Compounding Center: A Family Business More stats 507
Every sperm is sacred: Sequencing DNA from individual cells vs “humans as a whole.” More stats 501

Most Commented 

Post Comments
Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk 25
Knowing the tumor’s size and location, could we target treatment to THE ROI by applying imaging-guided intervention? 24
Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production 24
Is the Warburg Effect the cause or the effect of cancer: A 21st Century View? 23
Differentiation Therapy – Epigenetics Tackles Solid Tumors 22
Nitric Oxide and Immune Responses: Part 1 22
Nitric Oxide: Chemistry and function 22
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I 21
Nano-particles as Synthetic Platelets to Stop Internal Bleeding Resulting from Trauma 21
Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition 20
Personalized medicine gearing up to tackle cancer 19

Type 2:

“Open Access to Curation of Scientific Research” – BioMed e-Books Series

https://pharmaceuticalintelligence.com/biomed-e-books/

Launch on Amazon-KINDLE, KINDLE FIRE: 2013, 2014

Eight Authors: 40 articles — Any day on Amazon’s e-Books List

Volume 1: Seven Authors, 29 articles

Volume 2: Six Authors, 28 articles

Volume 3: Eight Authors, 43 articles

Volume 1: Eight Authors, 154 articles [65 posts by Larry, 56 posts by Aviva]

Volume 2: [Work-in-Progress]

Volume 3: [Work-in-Progress]

Type 3:

“Open Access to Curation of Scientific Research” – Scoop.it!

medical imaging of the heart

Cardiovascular Disease: Pharmaco-therapy

Drug Therapy for Heart Disease 

Curated by Aviva Lev-Ari, PhD, RN

“Open Access to Curation of Scientific Research” – Articles on this Topic covered in http://pharmaceuticalintelligence.com

“Open Access Publishing” is becoming the mainstream model: “Academic Publishing” has changed Irrevocably

https://pharmaceuticalintelligence.com/2012/10/25/open-access-publishing-is-becoming-the-mainstream-model-academic-publishing-has-changed-irrevocably/

Digital Publishing Promotes Science and Popularizes it by Access to Scientific 

Open-Access Publishing in Genomics

https://pharmaceuticalintelligence.com/2013/01/14/open-access-publishing-in-genomics/

Part Two

Comprehensive analysis of the phenomena of “Open Access to Curation of Scientific Research” is presented below by two curated articles:

Views of Thomas Lin, NYT, 1/17/2012 – Cracking Open the Scientific Process

A GLOBAL FORUM Ijad Madisch, 31, a virologist and computer scientist, founded ResearchGate, a Berlin-based social networking platform for scientists that has more than 1.3 million members.
Published: January 16, 2012 

The New England Journal of Medicine marks its 200th anniversary this year with a timeline celebrating the scientific advances first described in its pages: the stethoscope (1816), the use of ether foranesthesia (1846), and disinfecting hands and instruments before surgery (1867), among others.

Timothy Fadek for The New York Times

LIKE, FOLLOW, COLLABORATE A staff meeting at ResearchGate. The networking site, modeled after Silicon Valley startups, houses 350,000 papers.

For centuries, this is how science has operated — through research done in private, then submitted to science and medical journals to be reviewed by peers and published for the benefit of other researchers and the public at large. But to many scientists, the longevity of that process is nothing to celebrate.

The system is hidebound, expensive and elitist, they say. Peer review can take months, journal subscriptions can be prohibitively costly, and a handful of gatekeepers limit the flow of information. It is an ideal system for sharing knowledge, said the quantum physicist Michael Nielsen, only “if you’re stuck with 17th-century technology.”

Dr. Nielsen and other advocates for “open science” say science can accomplish much more, much faster, in an environment of friction-free collaboration over the Internet. And despite a host of obstacles, including the skepticism of many established scientists, their ideas are gaining traction.

Open-access archives and journals like arXiv and the Public Library of Science (PLoS) have sprung up in recent years. GalaxyZoo, a citizen-science site, has classified millions of objects in space, discovering characteristics that have led to a raft of scientific papers.

On the collaborative blog MathOverflow, mathematicians earn reputation points for contributing to solutions; in another math experiment dubbed the Polymath Project, mathematicians commenting on the Fields medalistTimothy Gower’s blog in 2009 found a new proof for a particularly complicated theorem in just six weeks.

And a social networking site called ResearchGate — where scientists can answer one another’s questions, share papers and find collaborators — is rapidly gaining popularity.

Editors of traditional journals say open science sounds good, in theory. In practice, “the scientific community itself is quite conservative,” said Maxine Clarke, executive editor of the commercial journal Nature, who added that the traditional published paper is still viewed as “a unit to award grants or assess jobs and tenure.”

Dr. Nielsen, 38, who left a successful science career to write “Reinventing Discovery: The New Era of Networked Science,” agreed that scientists have been “very inhibited and slow to adopt a lot of online tools.” But he added that open science was coalescing into “a bit of a movement.”

On Thursday, 450 bloggers, journalists, students, scientists, librarians and programmers will converge on North Carolina State University (and thousands more will join in online) for the sixth annual ScienceOnline conference. Science is moving to a collaborative model, said Bora Zivkovic, a chronobiology blogger who is a founder of the conference, “because it works better in the current ecosystem, in the Web-connected world.”

Indeed, he said, scientists who attend the conference should not be seen as competing with one another. “Lindsay Lohan is our competitor,” he continued. “We have to get her off the screen and get science there instead.”

Facebook for Scientists?

“I want to make science more open. I want to change this,” said Ijad Madisch, 31, the Harvard-trained virologist and computer scientist behind ResearchGate, the social networking site for scientists.

Started in 2008 with few features, it was reshaped with feedback from scientists. Its membership has mushroomed to more than 1.3 million, Dr. Madisch said, and it has attracted several million dollars in venture capital from some of the original investors of Twitter, eBay and Facebook.

A year ago, ResearchGate had 12 employees. Now it has 70 and is hiring. The company, based in Berlin, is modeled after Silicon Valley startups. Lunch, drinks and fruit are free, and every employee owns part of the company.

The Web site is a sort of mash-up of Facebook, Twitter and LinkedIn, with profile pages, comments, groups, job listings, and “like” and “follow” buttons (but without baby photos, cat videos and thinly veiled self-praise). Only scientists are invited to pose and answer questions — a rule that should not be hard to enforce, with discussion threads about topics like polymerase chain reactions that only a scientist could love.

Scientists populate their ResearchGate profiles with their real names, professional details and publications — data that the site uses to suggest connections with other members. Users can create public or private discussion groups, and share papers and lecture materials. ResearchGate is also developing a “reputation score” to reward members for online contributions.

ResearchGate offers a simple yet effective end run around restrictive journal access with its “self-archiving repository.” Since most journals allow scientists to link to their submitted papers on their own Web sites, Dr. Madisch encourages his users to do so on their ResearchGate profiles. In addition to housing 350,000 papers (and counting), the platform provides a way to search 40 million abstracts and papers from other science databases.

In 2011, ResearchGate reports, 1,620,849 connections were made, 12,342 questions answered and 842,179 publications shared. Greg Phelan, chairman of the chemistry department at the State University of New York, Cortland, used it to find new collaborators, get expert advice and read journal articles not available through his small university. Now he spends up to two hours a day, five days a week, on the site.

Dr. Rajiv Gupta, a radiology instructor who supervised Dr. Madisch at Harvard and was one of ResearchGate’s first investors, called it “a great site for serious research and research collaboration,” adding that he hoped it would never be contaminated “with pop culture and chit-chat.”

Mike Peel

EVOLUTION Michael Nielsen, a quantum physicist, says that as online tools slowly catch on, open science is coalescing into “a bit of a movement.”

Travis Dove for The New York Times

COME TOGETHER Bora Zivkovic, a chronobiology blogger, is a founder of  the ScienceOnline conference.

Dr. Gupta called Dr. Madisch the “quintessential networking guy — if there’s a Bill Clinton of the science world, it would be him.”

The Paper Trade

Dr. Sönke H. Bartling, a researcher at the German CancerResearch Center who is editing a book on “Science 2.0,” wrote that for scientists to move away from what is currently “a highly integrated and controlled process,” a new system for assessing the value of research is needed. If open access is to be achieved through blogs, what good is it, he asked, “if one does not get reputation and money from them?”

Changing the status quo — opening data, papers, research ideas and partial solutions to anyone and everyone — is still far more idea than reality. As the established journals argue, they provide a critical service that does not come cheap.

“I would love for it to be free,” said Alan Leshner, executive publisher of the journal Science, but “we have to cover the costs.” Those costs hover around $40 million a year to produce his nonprofit flagship journal, with its more than 25 editors and writers, sales and production staff, and offices in North America, Europe and Asia, not to mention print and distribution expenses. (Like other media organizations, Science has responded to the decline in advertising revenue by enhancing its Web offerings, and most of its growth comes from online subscriptions.)

Similarly, Nature employs a large editorial staff to manage the peer-review process and to select and polish “startling and new” papers for publication, said Dr. Clarke, its editor. And it costs money to screen for plagiarism and spot-check data “to make sure they haven’t been manipulated.”

Peer-reviewed open-access journals, like Nature Communications and PLoS One, charge their authors publication fees — $5,000 and $1,350, respectively — to defray their more modest expenses.

The largest journal publisher, Elsevier, whose products include The Lancet, Cell and the subscription-based online archive ScienceDirect, has drawn considerable criticism from open-access advocates and librarians, who are especially incensed by its support for the Research Works Act, introduced in Congress last month, which seeks to protect publishers’ rights by effectively restricting access to research papers and data.

In an Op-Ed article in The New York Times last week,Michael B. Eisen, a molecular biologist at the University of California, Berkeley, and a founder of the Public Library of Science, wrote that if the bill passes, “taxpayers who already paid for the research would have to pay again to read the results.”

In an e-mail interview, Alicia Wise, director of universal access at Elsevier, wrote that “professional curation and preservation of data is, like professional publishing, neither easy nor inexpensive.” And Tom Reller, a spokesman for Elsevier, commented on Dr. Eisen’s blog, “Government mandates that require private-sector information products to be made freely available undermine the industry’s ability to recoup these investments.”

Mr. Zivkovic, the ScienceOnline co-founder and a blog editor for Scientific American, which is owned by Nature, was somewhat sympathetic to the big journals’ plight. “They have shareholders,” he said. “They have to move the ship slowly.”

Still, he added: “Nature is not digging in. They know it’s happening. They’re preparing for it.”

Science 2.0

Scott Aaronson, a quantum computing theorist at the Massachusetts Institute of Technology, has refused to conduct peer review for or submit papers to commercial journals. “I got tired of giving free labor,” he said, to “these very rich for-profit companies.”

Dr. Aaronson is also an active member of online science communities like MathOverflow, where he has earned enough reputation points to edit others’ posts. “We’re not talking about new technologies that have to be invented,” he said. “Things are moving in that direction. Journals seem noticeably less important than 10 years ago.”

Dr. Leshner, the publisher of Science, agrees that things are moving. “Will the model of science magazines be the same 10 years from now? I highly doubt it,” he said. “I believe in evolution.

“When a better system comes into being that has quality and trustability, it will happen. That’s how science progresses, by doing scientific experiments. We should be doing that with scientific publishing as well.”

Matt Cohler, the former vice president of product management at Facebook who now represents Benchmark Capital on ResearchGate’s board, sees a vast untapped market in online science.

“It’s one of the last areas on the Internet where there really isn’t anything yet that addresses core needs for this group of people,” he said, adding that “trillions” are spent each year on global scientific research. Investors are betting that a successful site catering to scientists could shave at least a sliver off that enormous pie.

Dr. Madisch, of ResearchGate, acknowledged that he might never reach many of the established scientists for whom social networking can seem like a foreign language or a waste of time. But wait, he said, until younger scientists weaned on social media and open-source collaboration start running their own labs.

“If you said years ago, ‘One day you will be on Facebook sharing all your photos and personal information with people,’ they wouldn’t believe you,” he said. “We’re just at the beginning. The change is coming.”

 SOURCE:

Views of Célya Gruson-Daniel, October 29, 2012, MyScienceWork

Monday, October 29, 2012 Célya Gruson-Daniel
The Internet now makes it possible to publish and share billions of data items every day, accessible to over 2 billion people worldwide.  This mass of information makes it difficult, when searching, to extract the relevant and useful information from the background noise. It should be added that these searches are time-consuming and can take much longer than the time we actually have to spend on them. Today, Google and specialized search engines such as Google Scholar are based on established algorithms. But are these algorithms sufficiently in line with users’ needs? What if the web needed a human brain to select and put forward the relevant information and not just the information based on “popularity” and lexical and semantic operations?

This article is a translation of “Science et curation : nouvelle pratique du Web 2.0” available at:http://blog.mysciencework.com/2012/02/03/science-et-curation-nouvelle-pratique-du-web-2-0.html It was translated from French into English by Mayte Perea López.

Curation on the World Wide Web ©Beboy-Fotolia

Web 2.0: New practices, new uses

To address this need, human intermediaries, empowered by the participatory wave of web 2.0, naturally started narrowing down the information and providing an angle of analysis and some context. They are bloggers, regular Internet users or community managers – a new type of profession dedicated to the web 2.0. A new use of the web has emerged, through which the information, once produced, is collectively spread and filtered by Internet users who create hierarchies of information. This “popularization of the web”therefore paves the way to a user-centered Internet that plays a more active role in finding means to improve the dissemination of information and filter it with more relevance. Today, this new practice has also been categorized and is known as curation.

The term “curation” was borrowed from the world of fine arts. Curators are responsible for the exhibitions held in museums and galleries. They build these exhibitions and act as intermediaries between the public and works of art. In contemporary art, the curator’s role is also to interpret works of art and discover new artists and trends of the moment. In a similar way on the web, the tasks performed by content curators include the search, selection, analysis, editorial work and dissemination of information. Curators can also share online the most relevant information on a specific subject. Instead of acting as mere echo chambers, they provide some context for their searches. For example, they address niche topics and themes that do not stand out in a traditional search. They prioritize the information and are able to find new means of presenting it, new types of visualizationTheir role is, therefore, to find new formats, faster and more direct means of consultation for Internet users, in a context in which the time we spend reading the information is more and more limited. Curation on the web has a social and relational dimension that plays a central role in the curator’s work. Anyone can act as a curator and personalize information, providing an angle that he or she invites us to discover. This means that curation can be carried out by individuals who do not have an institutional footing. The expression “powered by people” exemplifies this possibility of democratizing information searches.

The world of scientific research and culture is no exception to this movement. The web 2.0 offers the scientific community and its surrounding spheres the opportunity to discover new tools that transform practices and uses, not only of researchers, but also of all the actors of scientific and technical culture (STC).

©Zothen-Fotolia

Curation: an Essential Practice to Manage “Open Science”

The web 2.0 gave birth to new practices motivated by the will to have broader and faster cooperation in a more free and transparent environment. We have entered the era of an “open” movement: “open data”, “open software”, etc. In science, expressions like “open access” (to scientific publications and research results) and “open science” are used more and more often.

The concept of “open science” emerged from the web and created bigger and bigger niches all around the planet. Open science and its derivatives such as open access make us dream of an era of open, collective expertise and innovation on an international scale. This catalyst in the field of science is only possible on one condition: that it be accompanied by the emergence of a reflection on the new practices and uses that are essential to its conservation and progress. Sharing information and data at the international level is very demanding in terms of management and organization. As a result, curation has established itself in the realm of science and technology, both in the research community and in the world of scientific and technical culture.

Curation: Collaborative Bibliographic Management for the Researcher 2.0

In the world of research, curation appears as a logical extension of the literature review and bibliographic search, the pillars of a researcher’s work. Curation on the web has brought a new dimension to this work of organizing and prioritizing information. It makes it easier for researchers to collaborate and share, while also bringing to light some works that had previously remained in the shadows.

Mendeley and Zotero are both search and bibliographic management tools that assist you in the creation of an online library. Thus, it is possible to navigate in this mass of bibliographic data, referenced by the researcher, through multiple gateways: keywords, authors’ names, date of publication, etc. In addition, these programs make it possible to generate automatically article bibliographies in the formats specified by each scientific journal. What is new about these tools, apart from the “logistical” aid they provide, is that they are based on collaboration and sharing. Mendeley and Zotero let you create private or public groups. These groups make it possible to share a bibliography with other researchers. They also give access to discussion forums that are useful for sharing with international researchers. Other tools like EndNote and Papersexist, but these paid softwares are less collaborative.

New platforms, real scientific social networks, have also appeared. The leading platform ResearchGate was founded in 2008 and now counts 1.9 million users (august 2012). It is an online search platform, but it is used above all for social interaction. Researchers can create a profile and discussion groups, make their work available online, job hunt, etc. Other professional social networks for researchers have emerged, among them MyScienceWork, which is devoted to open access.

Curation, in the era of open science, accelerates the dissemination of information and provides access to the most relevant parts. Post-publication comments add value to the content. Apart from the benefits for the community, these new practices change the role of researchers in society by offering them new public spaces for expression. Curation on the web opens the way towards the development of an e-reputation and a new form of celebrity in the world of international science. It gives everyone the opportunity to show the cornerstones of their work in the same way that the research notebooks of Hypothèses.orgwere used in Humanities and Social Sciences. This system based on the dual role of “observer/observed” may also impose limits on researchers who would have to be more thorough in the choice of the articles they list.

Have we entered the era of the “researcher 2.0”? Undoubtedly, even if it is still limited to a small group of people. The tools described above are widely used for bibliographic management but their collaborative function is still less used. It is difficult to change researchers’ practices and attitudes. To move from a closed science to an open science in a world of cutthroat competition, researchers will have to grope their way along. These new means of sharing are still sometimes perceived as a threat to the work of researchers or as an excessively long and tedious activity.

Curation and Scientific and Technical Culture: Creating Hybrid Networks

Another area, where there are most likely fewer barriers, is scientific and technical culture. This broad term involves different actors such as associations, companies, universities’ communication departments, CCSTI (French centers for scientific, technical and industrial culture), journalists, etc. A number of these actors do not limit their work to popularizing the scientific data; they also consider they have an authentic mission of “culturing” science. The curation practice thus offers a better organization and visibility to the information. The sought-after benefits will be different from one actor to the next. University communication departments are using the web 2.0 more and more to promote their values; this is the case, for example, for the FrenchUniversité Paris 8. For companies, curation offers the opportunity to become a reference on the themes related to their corporate identity. MyScienceWork, for example, began curating three collections surrounding the key themes of its project. The key topics of its identity are essentially open accessnew uses and practices of the web 2.0 in the world of science and “women in science”. It is essential to keep abreast of the latest news coming from large institutions and traditional media, but also to take into account bloggers’ articles and links that offer a different viewpoint.

Some tools have also been developed in order to meet the expectations of these various users. Pearltreesand Scoopit are non-specialized curation tools that are widely used by the world of Scientific and Technical Culture. Pearltrees offers a visual representation in which each listed page is presented as a pearl connected to the others through branches. The result: a prioritized data tree. These mindmaps can be shared with one’s contacts. A good example of this is the work done by Sébastien Freudenthal, who uses this tool on a daily basis and offers rich content listed by theme in the field of Sciences and Web. Scoopit offers a more traditional presentation with a nice page layout that looks like a magazine. It enables you to list articles quickly and almost automatically, thanks to a plugin, and also to share them. A special tool for the “world” of Technical and Scientific Culture is the social network of scientific culture Knowtex that, in addition to its referencing and links assessment functions, seeks to create a space interconnecting journalists, artists, communicators, designers, bloggers, researchers, etc.

These different tools are used on a daily basis by various actors of technical and scientific culture, but also by researchers, teachers, etc. They gather these communities around a shared practice and favor multiple conversations. The development of these hybrid networks is surely a cornerstone in the building of open science, encouraging the creation of new ties between science and society that go beyond the traditional geographical limits.

Un grand merci à Antoine Blanchard pour sa participation et relecture de l’article.

Find out more:

« Curation is the new research, »… et le nouveau média, Benoit Raphael, 2011http://benoitraphael.com/2011/01/17/curation-is-the-new-search/

La curation : la révolution du webjournalisme?, non-fiction.fr http://www.nonfiction.fr/article-4158-la_curation__la_revolution_du_webjournalisme_.htm

La curation : les 10 raisons de s’y intéresser, Pierre Tran http://pro.01net.com/editorial/529947/la-curation-les-10-raisons-de-sy-interesser/

Curation : quelle valeur pour les entreprises, les médias, et sa « marque personnelle »?, Marie-Laure Vie http://marilor.posterous.com/curation-et-marketing-de-linformation

Cracking Open the Scientific Process, Thomas Lin, New York Times http://www.nytimes.com/2012/01/17/science/open-science-challenges-journal-tradition-with-web-collaboration.html?_r=4&pagewanted=1

La « massification » du web transforme les relations sociales, Valérie Varandat, INRIA http://www.inria.fr/actualite/actualites-inria/internet-du-futur

Internet a révolutionné le métier de chercheur, AgoraVoxhttp://www.agoravox.fr/actualites/technologies/article/internet-a-revolutionne-le-metier-103514

Gérer ses références numériques, Université de Genèvehttp://www.unige.ch/medecine/udrem/Unit/actualites/biblioManager.html

Notre liste Scoop-it : Scientific Social Network, MyScienceWork

SOURCE:

In French:

Summary

This article has two parts, the first presents a pioneering experience in Curation of Scientific Research in an Open Access Online Scientific Journal,  in a BioMed e-Books Series and in curation of a Scoop.it! Journal on Medical Imaging.

The second Part, presents Views of two Curators on the transformation of Scientific Publishing and the functioning of the Scientific AGORA (market place in the Ancient Greek CIty of Athena).

The CHANGES described above are irrevocable and foster progress of civilization by provision of ACCESS to the Scientific Process and Resources via collaboration among peers.

Part Three

SOURCE:

http://www.nytimes.com/2013/04/08/health/for-scientists-an-exploding-world-of-pseudo-academia.html?pagewanted=1&_r=0&emc=eta1 

Scientific Articles Accepted (Personal Checks, Too)

Kevin Moloney for The New York Times

Jeffrey Beall, a research librarian at the University of Colorado at Denver, has developed a blacklist of “predatory” journals.

By 

Published: April 7, 2013

The scientists who were recruited to appear at a conference called Entomology-2013 thought they had been selected to make a presentation to the leading professional association of scientists who study insects.

But they found out the hard way that they were wrong. The prestigious, academically sanctioned conference they had in mind has a slightly different name: Entomology 2013 (without the hyphen). The one they had signed up for featured speakers who were recruited by e-mail, not vetted by leading academics. Those who agreed to appear were later charged a hefty fee for the privilege, and pretty much anyone who paid got a spot on the podium that could be used to pad a résumé.

“I think we were duped,” one of the scientists wrote in an e-mail to the Entomological Society.

Those scientists had stumbled into a parallel world of pseudo-academia, complete with prestigiously titled conferences and journals that sponsor them. Many of the journals and meetings have names that are nearly identical to those of established, well-known publications and events.

Steven Goodman, a dean and professor of medicine at Stanford and the editor of the journal Clinical Trials, which has its own imitators, called this phenomenon “the dark side of open access,” the movement to make scholarly publications freely available.

The number of these journals and conferences has exploded in recent years as scientific publishing has shifted from a traditional business model for professional societies and organizations built almost entirely on subscription revenues to open access, which relies on authors or their backers to pay for the publication of papers online, where anyone can read them.

Open access got its start about a decade ago and quickly won widespread acclaim with the advent of well-regarded, peer-reviewed journals like those published by the Public Library of Science, known as PLoS. Such articles were listed in databases like PubMed, which is maintained by the National Library of Medicine, and selected for their quality.

But some researchers are now raising the alarm about what they see as the proliferation of online journals that will print seemingly anything for a fee. They warn that nonexperts doing online research will have trouble distinguishing credible research from junk. “Most people don’t know the journal universe,” Dr. Goodman said. “They will not know from a journal’s title if it is for real or not.”

Researchers also say that universities are facing new challenges in assessing the résumés of academics. Are the publications they list in highly competitive journals or ones masquerading as such? And some academics themselves say they have found it difficult to disentangle themselves from these journals once they mistakenly agree to serve on their editorial boards.

The phenomenon has caught the attention of Nature, one of the most competitive and well-regarded scientific journals. In a news report published recently, the journal noted “the rise of questionable operators” and explored whether it was better to blacklist them or to create a “white list” of those open-access journals that meet certain standards. Nature included a checklist on “how to perform due diligence before submitting to a journal or a publisher.”

Jeffrey Beall, a research librarian at the University of Colorado in Denver, has developed his own blacklist of what he calls “predatory open-access journals.” There were 20 publishers on his list in 2010, and now there are more than 300. He estimates that there are as many as 4,000 predatory journals today, at least 25 percent of the total number of open-access journals.

“It’s almost like the word is out,” he said. “This is easy money, very little work, a low barrier start-up.”

Journals on what has become known as “Beall’s list” generally do not post the fees they charge on their Web sites and may not even inform authors of them until after an article is submitted. They barrage academics with e-mail invitations to submit articles and to be on editorial boards.

One publisher on Beall’s list, Avens Publishing Group, even sweetened the pot for those who agreed to be on the editorial board of The Journal of Clinical Trails & Patenting, offering 20 percent of its revenues to each editor.

One of the most prolific publishers on Beall’s list, Srinubabu Gedela, the director of the Omics Group, has about 250 journals and charges authors as much as $2,700 per paper. Dr. Gedela, who lists a Ph.D. from Andhra University in India, says on his Web site that he “learnt to devise wonders in biotechnology.”

Another Beall’s list publisher, Dove Press, says on its Web site, “There are no limits on the number or size of the papers we can publish.”

Open-access publishers say that the papers they publish are reviewed and that their businesses are legitimate and ethical.

“There is no compromise on quality review policy,” Dr.Gedela wrote in an e-mail. “Our team’s hard work and dedicated services to the scientific community will answer all the baseless and defamatory comments that have been made aboutOmics.”

But some academics say many of these journals’ methods are little different from spam e-mails offering business deals that are too good to be true.

Paulino Martínez, a doctor in Celaya, Mexico, said he was gullible enough to send two articles in response to an e-mail invitation he received last year from The Journal of Clinical Case Reports. They were accepted. Then came a bill saying he owed $2,900. He was shocked, having had no idea there was a fee for publishing. He asked to withdraw the papers, but they were published anyway.

“I am a doctor in a hospital in the province of Mexico, and I don’t have the amount they requested,” Dr. Martínez said. The journal offered to reduce his bill to $2,600. Finally, after a year and many e-mails and a phone call, the journal forgave the money it claimed he owed.

Some professors listed on the Web sites of journals on Beall’s list, and the associated conferences, say they made a big mistake getting involved with the journals and cannot seem to escape them.

Thomas Price, an associate professor of reproductive endocrinology and fertility at the Duke University School of Medicine, agreed to be on the editorial board of The Journal of Gynecology & Obstetrics because he saw the name of a well-respected academic expert on its Web site and wanted to support open-access journals. He was surprised, though, when the journal repeatedly asked him to recruit authors and submit his own papers. Mainstream journals do not do this because researchers ordinarily want to publish their papers in the best journal that will accept them. Dr. Price, appalled by the request, refused and asked repeatedly over three years to be removed from the journal’s editorial board. But his name was still there.

“They just don’t pay any attention,” Dr. Price said.

About two years ago, James White, a plant pathologist at Rutgers, accepted an invitation to serve on the editorial board of a new journal, Plant Pathology & Microbiology, not realizing the nature of the journal. Meanwhile, his name, photograph and résumé were on the journal’s Web site. Then he learned that he was listed as an organizer and speaker on a Web site advertising Entomology-2013.

“I am not even an entomologist,” he said.

He thinks the publisher of the plant journal, which also sponsored the entomology conference, — just pasted his name, photograph and résumé onto the conference Web site. At this point, he said, outraged that the conference and journal were “using a person’s credentials to rip off other unaware scientists,” Dr. White asked that his name be removed from the journal and the conference.

Weeks went by and nothing happened, he said. Last Monday, in response to this reporter’s e-mail to the conference organizers, Jessica Lincy, who said only that she was a conference member, wrote to explain that the conference had “technical problems” removing Dr. White’s name. On Tuesday, his name was gone. But it remained on the Web site of the journal.

Dr. Gedela, the publisher of the journals and sponsor of the conference, said in an e-mail on Thursday that Dr. Price and Dr. White’s names remained on the Web sites “because of communication gap between the EB member and the editorial assistant,” referring to editorial board members. That day, their names were gone from the journals’ Web sites.

“I really should have known better,” Dr. White said of his editorial board membership, adding that he did not fully realize how the publishing world had changed. “It seems like the Wild West now.”

This article has been revised to reflect the following correction:

Correction: April 8, 2013

An earlier version of this article misstated the name of a city in Mexico that is home to a doctor who sent articles to a pseudo-academic journal. It is Celaya, not Ceyala.

SOURCE:

http://www.nytimes.com/2013/04/08/health/for-scientists-an-exploding-world-of-pseudo-academia.html?pagewanted=1&_r=0&emc=eta1 

Read Full Post »